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ABSTRACT
PROTEOLYTIC ACTIVATION BY ADAMTS3 DEFINES DISTINCT MECHANISMS
OF LYMPHANGIOGENESIS MEDIATED BY VEGFC AND VEGFD
Hung M. Bui
Mark L. Kahn
Lymphangiogenesis is supported by two homologous VEGFR3 ligands, VEGFC and
VEGFD. VEGFC is required for lymphatic development, while VEGFD is not. VEGFC
and VEGFD are proteolytically cleaved after cell secretion in vitro, and recent studies
have implicated the protease ADAMTS3 and the secreted factor CCBE1 in this process.
How ligand proteolysis is controlled at the molecular level and how it regulates
lymphangiogenesis remain poorly understood because these complex molecular
interactions have been difficult to follow ex vivo and test in vivo. In the present study, we
use new biochemical and cellular tools to demonstrate that an ADAMTS3-CCBE1
complex can form independently of VEGFR3 is required to convert VEGFC but not
VEGFD to an active ligand. Consistent with these ex vivo findings, mouse genetic studies
demonstrate that ADAMTS3 is required for lymphatic development in a manner identical
to VEGFC and CCBE1, and that CCBE1 is required for lymphangiogenesis stimulated by
VEGFC but not VEGFD in vivo. These studies reveal that lymphangiogenesis is
regulated by two distinct proteolytic mechanisms of ligand activation: one in which
VEGFC activation by ADAMTS3 and CCBE1 spatially and temporally patterns
developing lymphatics, and one in which VEGFD activation by a distinct proteolytic
mechanism may stimulate lymphatic growth during inflammation or wound healing.
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CHAPTER ONE
Introduction
1.1

Lymphatic system

In vertebrates, lymphatics are a part of the circulatory system that develops from preexisting blood vessels. The lymphatic system plays important roles, not only by
transporting interstitial fluid and absorbing lipids, but also by providing a conduit for
immune cells. The discovery of lymphatic vasculature dates back to the ancient time in
the record of Hippocrates (5th century BCE) and Herophilos (3rd century BCE). The idea
of lymphatic vasculature was further developed in 17th century by the works of William
Harvey, who discovered a separate system from the blood circulation; that was followed
by Thomas Bartholin's description on lymphatic vessels. However, it was not until the
20th century that the anatomic features of the lymphatic vasculature were extensively
characterized. Florence Sabin was the first who suggested cardinal veins are the initial
site of lymphatic development (Sabin, 1902), which has recently been demonstrated by
modern technologies of lineage tracing and live imaging (Yaniv et al., 2006; Srinivasan
et al., 2007). Discoveries on lymphatic system have bloomed in recent years that provide
better understanding of the system, as well as facilitate new approaches to address
unanswered questions.
The lymphatic system is a network of lymphatic vessels, lymph nodes, the spleen, and the
thymus (Fig. 1). First, lymph vessels, aka lymphatics, carry lymph (or interstitial fluid) in
one direction from blood vessels back to the heart. Lymphatics consist of a hierarchy of
transporting vessels that are separated by lymphatic valves (mentioned later). Secondly,
1

lymph nodes (LN) are secondary lymphoid organs, in which lymphocytes come into
contact with antigen to trigger an immune response. Primary lymphoid organs (like bone
marrow), on the other hand, are the sites of lymphocyte generation. LNs share mutual
development with lymphatic vasculature during early stages of lymphatic development,
which allows LNs to act as junctions between lymphatic vasculature and lymphoid
tissues. This connection enables antigens to enter mature LNs via afferent lymphatic
vessels and to present to lymphocytes in the LN. Thirdly, the spleen is a bean-shaped
organ located in the upper left side of the abdomen, which functions as blood filter. The
macrophage lining in the spleen engulfs and eliminates pathogens and dead cells.
Another important function of the spleen is to generate and release lymphocytes into
blood stream. Lastly, the thymus is a lymphoid tissue located in the upper chest under the
breastbone. The thymus only develops until the time of puberty when it shrinks and
gradually blends in with surrounding tissues. In the thymus, immature lymphocytes
develop into T lymphocytes (T cells) by the thymic environment. While maturing and
multiplying in the thymus, each T cell is programmed to respond to a specific chemical
identification marker, i.e. an antigen.

Figure 1. The human lymphatic system.
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1.2

Lymphangiogenesis

Lymphangiogenesis is defined as a process of lymphatic vessel formation from preexisting blood vessels.
1.2.1

Early development stage

In mice, lymphatic endothelial cells (LECs) arise from pre-existing blood endothelial
586aLymph
nodeof
development,
S. Blum and R. Pabst
cells via
process
stepwiseK.specification
(Fig. 2).
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Figure 2. Early development of mouse lymphatic system (E9.0 – E11.5) (adapted When the lymphendothelia
from Blum and Pabst, 2006).
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marker of this process is the transcription factor Lyve1, which is specifically expressed by
Sabin’s concept. They showed that endothelial cells
(ECs) from the anterior cardinal vein start to express
LYVE1 around embryonic day (E) 9.0–9.5 in the mouse
progenitors is the transcription factor Prox1 (Wigle
(Oliver, 2004). It still remains unclear which gene or the
molecule produced is responsible for this expression in
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vivo and whether LYVE1 expression is essential for the
metamorphosis from venous endothelial cell (VEC)
to LEC. Studies investigating LYVE1 expression in ECs
derived from mouse embryonic stem (ES) cells suggest
that this expression is induced via VEGFR-3 signalling

as previously argued by Wigle et al. (2002)
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vein (Fig. 1). This expression occurs around
few hours after LYVE1 expression, and is re
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venous BECs, which later form LEC progenitors (Oliver, 2004). The first marker of true
LEC

transcription factors Sox18 and Coup-TFII are required for Prox1 expression and
maintenance. Whereas loss of Sox18 results in the absence of LEC progenitors (François
et al., 2008), COUP-TFII is essential for the specification of lymphatic endothelial cells
(LECs). COUP-TFII down regulates Notch activity, resulting in Prox1 expression
(Srinivasan et al., 2010). By the end of the “lymphatic bias” stage, PROX1+ cells, now
called LEC progenitors, show increased expression of lymphatic genes and decreased
expression of blood endothelial genes.
The “lymphatic specification” stage begins by E10.5, when LECs start to sprout from the
cardinal vein. A subset of LEC progenitors expresses PODOPLANIN (PLDN), a specific
marker of true LECs, and bud from the CV (Yang et al., 2012). After departing from the
vein, LECs connect with each other through VE-Cadherin adhesion junctions. Finally,
LECs migrate along the embryo’s anterior-posterior axis to form intermediate structures
called ‘lymph sacs’ by E11.5. This process requires signaling from vascular endothelial
growth factor-C (VEGFC) via its receptor, vascular endothelial growth factor receptor 3
(VEGFR3), and co-factor, Neuropilin 2 (Nrp2) (Jeltsch et al., 1997; Yuan et al., 2002).
PROX1+ LEC progenitors fail to exit from the CV in Vegfc-deficient mice (Karkkainen et
al., 2004). VEGFC/VEGFR3 in vivo activity is specific for lymphatic growth, since only
LECs are responsive to VEGFC growth signaling (Jeltsch et al., 1997). Several
regulatory proteins also influence the process of LEC migration. Ephrin B2 facilitates
VEGFR3 internalization, which is required for VEGFR3 activation (Wang et al., 2010).
At this point, the mutual development of the lymphatic vasculature and the lymphoid
organs, such as LNs, halts and the two systems develop independently of each other
(Yokota et al., 1999; Muller et al., 2003; Cupedo et al., 2004).
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1.2.2

Lymphatic vasculature

The lymphatic vasculature continues to develop through sprouting of lymph sac LECs to
form a primitive lymphatic plexus at E14.5. This structure remodels further after E15.5 to
establish the mature lymphatic system, in which the interstitial fluid (lymph) enters the
1064

lymphatic system through initial lymphatic capillaries (Fig. 3).
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vessels, which contain bicuspid one-way valves located at irregular intervals, and
incomplete coverage by smooth muscle cells (Sacchi et al., 1997). They have a dual role
— first, as lymph transporters, pumping at regions containing smooth muscle cells, and
second, as fluid absorbers, where the smooth muscle cell layer is absent. Pre-collecting
vessels drain into the larger collecting vessels. Collecting lymphatic vessels have
complete smooth muscle cell coverage of their walls to facilitate lymph transport and
intraluminal valves form to prevent retrograde flow. The collecting lymphatics bring fluid
into and out of the LN via afferent and efferent vessels, respectively. They connect to the
blood circulation at the site of lymphovenous valves, located at the junctions of the left
and right subclavian veins and the lymphatic duct. These valves prevent blood from
filling the lymphatic system through a mechanism involving CLEC2, the platelet receptor
activated in response to LECs (Hess et al., 2014). By contracting, collecting vessels force
lymph back to the blood circulation via the lymphovenous valves, completing the oneway flow of lymph facilitated by the lymphatic system (Fig. 4).
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Figure 1. The lymphatic system. Adapted with permission from Quere [9].

Figure 4. The lymphatic vasculature and direction of lymph flow (adapted from Margeris and Black,
2012).
2. ANATOMY OF THE LYMPHATIC
SYSTEM
The lymphatic system is composed of a network of
vessels, termed lymphatics, lymph nodes and lymphoid
organs. The interstitial fluid enters through the small
lymphatic capillaries (also called initial or terminal
lymphatics) that gradually combine to form larger
diameter vessels, namely the pre-collectors, collectors,

Burke [10] investigated the structure of the lymphatic

6 capillaries, and speculated that they could function as
valves, although at that time no proof was provided.
2.2. Pre-collecting lymphatics
The pre-collecting lymphatics connect the capillaries to
the collecting vessels. They contain bicuspid one-way

1.2.3

Lymphatic defects

Defects in lymphatic vasculature formation can lead to disruption of the drainage of
interstitial fluids back into the cardiovascular system, resulting in lymphedema,
chylothorax, and other consequences. One of the consequences of lymphatic defects is
primary lymphedema, caused by hereditary genetic disorders. Primary lymphedema is
associated with disordered lymph drainage, results in lymph dysplasia or lethality (in case
of some homozygous mutants). For example, in Hennekam’s syndrome, mutations in
CCBE1 (CCBE1 collagen and calcium binding EGF domain -1) lead to lymphedema and
mental retardation in human patients (Alders et al., 2009). CCBE1-null mice die due to
lack of lymphatic vasculature, which results in respiratory failure at birth (Jakus et al.,
2014). In Milroy’s syndrome, a missense mutation in the VEGFR3 kinase domain leads
to congenital lymphedema in humans, and limb swelling in Chy mice (a mouse model of
Milroy’s disease) (Butler et al., 2007; Karkkainen et al., 2001). Another consequence of
lymphatic defects is obesity due to the fact that intestinal lymphatic vessels are
responsible for lipid absorption in the form of chylomicrons and fat transportation in the
bloodstream. The link between lymphatic vasculature defects and obesity were
demonstrated in a mouse model heterozygous for a PROX1 mutation, which developed
obesity (Harvey et al., 2005). Moreover, Chy mice have abnormal fat accumulation,
along with the reported lymphedema (Rutkowski et al., 2010). Just as lymphatic defects
have been shown to cause excess fat deposition, it appears that lymphatic defects can
result in obesity-associated metabolic diseases such as diabetes and cardiovascular
diseases (e.g. atherosclerosis). In addition, lymphatic vasculature has also been reported
to be a route for tumor cells to metastasize in cancer (reviewed in Alitalo, 2011). The
7

high interstitial pressure in malignant tumors enables cells to enter lymphatic vessels and
to travel to different sites in the body through lymph flow, resulting in metastasis.

Figure 5. Examples of Milroy’s patients (adapted from Gordon et al., 2013).
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1.3

Vascular endothelial growth factor (VEGF-) C

1.3.1

Vascular endothelial growth factor family

VEGF/ PDGF (platelet-derived growth factor) family is a group of the cysteine-knot
superfamily of signaling molecules, which are characterized by the presence of eight
conserved cysteine residue forming the cysteine-knot structure in the VEGF-homologydomain (VHD) (Vitt et al., 2001). In mammals, the VEGF family includes five wellknown ligands, VEGFA, VEGFB, VEGFC, VEGFD and PIGF (placental-induced growth
factor), plus two less studied ligands, VEGFE and VEGFF. These molecules display
various essential roles during embryonic development (including angiogenesis –
sprouting

process

of

new

blood

capillaries

from

pre-existing

vessels;

and

lymphangiogenesis) and in adulthood.

Figure 6. Sequence alignment of VEGF family members and their isoforms (Takahashi et al., 2005).

9

A. VEGFA
VEGFA (aka VEGF) was first characterized as a vascular permeability factor in tumor
cells (Senger et al., 1983), thus its function was identified as tumor-secreted cytokine
stimulating angiogenesis (Rini and Small, 2005). Biochemical studies further revealed
that VEGFA exists in four mature isoforms (by alternative splicing) including VEGF121,
VEGF165, VEGF189 and VEGF206 (Tischer et al., 1991); among which, VEGF165 is the
dominant isoform. In vitro, VEGFA has been shown as a pro-angiogenic protein by
inducing proliferation and tube formation of endothelial cells (Leung et al., 1989); as
well as a potent survival factor for these cells (Gerber et al., 1998). Furthermore, in vivo
study of VEGFA demonstrated the protein to be indispensable during embryogenesis as
deletion of Vegfa gene leads to cardiovascular abnormalities, thus resulting in embryonic
lethality (Carmeliet et al., 1996). VEGFA also regulates a number of angiogenic
processes such as wound healing and tumor growth in adult animals (Brown et al., 1992;
Larcher et al., 1998; Rossiter et al., 2004).

B. VEGFB
Although VEGFB was demonstrated to promote angiogenesis through activation of AKT
and eNOS pathways (Silvestre et al., 2003), the precise role of VEGFB in vivo remains
unknown. This is illustrated by the fact that Vegfb-deficient mice are viable and fertile,
with a mild phenotype consisting of smaller hearts and impaired recovery from cardiac
ischemia (Bellomo et al., 2003). Expression of VEGFB in vitro yields two different
isoforms (by alternative splicing), VEGF-B167 and VEGF-B186; the former associates with
10

membrane glycosaminoglycans for extracellular matrix (ECM) anchoring, while the latter
is likely to diffuse freely throughout the body (Olofsson et al., 1996).

C. VEGFC
VEGFC is the only VEGF family member that induces selective lymphangiogenesis
without promoting angiogenesis during embryonic development in vivo (Jeltsch et al.,
1997). Mice with complete loss of Vegfc lacked lymphatic vasculature and died of
edema, whereas heterozygous Vegfc-deficient mice showed cutaneous lymphedema and
hypoplasia lymphatic vessels (Karkkainen et al., 2004). In addition, overexpression of
VEGFC in adult tumor transgenic mice showed higher lymphatic invasion and metastatic
potential in various types of cancers (Mandriota et al., 2001; Wang et al., 2013; Fujimoto
et al., 2004; He et al., 2004). These data demonstrate an indispensable role of VEGFC
during early lymphangiogenesis, as well as maintaining a role in lymphangiogenesis in
adult mice. More insights on VEGFC properties have been revealed from in vitro studies.
Unlike VEGFA or VEGFB, VEGFC protein structure contains two peptide extensions (at
both N- and C- termini) flanking the central VHD. This illustrates why VEGFC is
generated as a precursor protein, which requires to be proteolytically processed to gain
full activation as an active ligand (mentioned later). Interestingly, among the members of
the VEGF family, VEGFC is highly homologous to VEGFD despite the fact that their
biological functions are very different. How the two homologous proteins plays different
roles in lymphangiogenesis remains unanswered yet.

11

D. VEGFD
VEGFD is highly homologous to VEGFC, in term of protein structure (Orlandini et al.,
1996; Achen et al., 1998) and also acts as a lymphatic factor by driving lymphatic
endothelial and vessel growth in adult animals (Rissanen et al., 2003; Saaristo et al.,
2002). Nevertheless, loss of VEGFD does not alter lymphatic development in the mouse
or fish (Koch et al., 2009; Astin et al., 2014). It is not yet clear how VEGFD works in
vivo as a dispensable factor during early lymphangiogenesis but becomes active in adult
animals. On the other hand, in vitro studies showed that VEGFD also undergoes
proteolytic processing (McColl et al., 2007), like VEGFC, to gain its active state.
Although it is not yet known exactly how VEGFC and VEGFD ligands are
proteolytically regulated, it is interesting to understand the relationship of these two
lymphatic factors and what makes them distinctively different towards regulating
lymphangiogenesis.
E. The other VEGF family members
PIGF, originally discovered in the placenta, is a dispensable angiogenic factor as Pigf –
deficient mice showed impairs in angiogenesis and collateral growth (Carmeliet et al.,
2001). Overexpression of PIGF in transgenic mice enhanced vascular permeability and
led to an increase in number of skin blood vessels (Odorisio et al., 2002; Oura et al.,
2003). VEGFE and VEGFF are the least studied of the factors. While VEGFE, especially
its VEGF-ENZ-2 isoform (Lyttle et al., 1994) is regarded as a potent angiogenic factor
(Meyer et al., 1999); the functional activity of VEGFF (identified from viper venom) is
not yet known.
12

1.3.2

VEGF receptors and VEGFR3 (FLT4)

The VEGF-member ligands induce signaling cascades via three receptor tyrosine kinases
(RTKs): VEGFR1, expressed in monocytes and macrophages, VEGFR2, expressed in
vascular endothelial cells, and VEGFR3, expressed in lymphatic endothelial cells. These
receptors share certain common aspects with other RTK families like the platelet-derived
growth factor receptors (PDGFRs) and the epidermal growth factor receptors (EGFRs).
Like these receptors, the VEGF- receptors dimerize in order to be activated and to
transduce intracellular signals. The VEGF- receptors are composed of seven extracellular
immunoglobin

(Ig)-like

loops,

a

transmembrane

domain,

an

autoinhibitory

juxtamembrane domain, a split tyrosine kinase domain and intracellular C-terminal tail
(Zachary and Gliki, 2001).
VEGFR signaling is initiated by binding of dimeric VEGF ligands to an IgG-like domain
of the receptors, either in a cis (from the same cell) or trans (from adjacent cells) manner.
VEGFR dimerization is “ligand-mediated”, meaning that receptor dimerization is solely
dependent on ligand-receptor interactions (review in Lemmon and Schlessinger, 2010),
which are further stabilized by contact points between the two extracellular domains
(Yang et al., 2010). When the receptor is inactive, the catalytic kinase domain is autoinhibited by the juxtamembrane domain. Juxtamembrane autoinhibition acts in cis to
make stable contacts with the kinase domain of the same receptor, thus preventing
phosphorylation of the catalytic tyrosine residues (Nolen et al., 2004). In accordance with
the general model of tyrosine kinase receptor activation, VEGFRs dimerize upon ligand
binding, leading to trans-phosphorylation of the receptor tyrosines, which in turn
weakens the cis- autoinhibitory juxtamembrane domain interaction (Hubbard, 2004). The
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autophosphorylation

of

RTKs

occurs

in

a

precise

order.

“First-phase”

autophosphorylation refers to phosphorylation of specific tyrosine residues that enhances
the kinase catalytic activity (Favelyukis et al., 2001). Subsequent autophosphorylation
events generate docking phosphotyrosine sites, which recruit cytoplasmic signaling
molecules containing Src homology-2 (SH2) and/or Phosphotyrosine-binding (PTB)
domains (Pawson, 2004; Schlessinger and Lemmon, 2003). These molecules are
recruited to RTKs either through direct binding to the receptor phosphotyrosines or
indirectly via docking proteins such as Gab1 (the Grb-associated binder) (Gu and Neel,
2003). These docking proteins then recruit and phosphorylate downstream effector
kinases. With multiple phosphotyrosine residues in the catalytic kinase domain, activated
receptors could trigger multiple signaling cascades, thus acting as a node in a complex
signaling network.
VEGFR3 (or FLT4) regulates early angiogenesis but becomes a lymphatic-specific RTK
around mid-gestation onwards (reviewed in Olsson et al., 2006). This receptor is
synthesized as a 195kDa protein precursor, which is proteolytically cleaved in the fifth
Ig-like loop resulting in a N-terminal peptide disulfide-bonded to the rest of the protein
(Pajusola et al., 1994). Human VEGFR3, by alternative splicing, exists as two protein
isoforms: predominant VEGFR3-long and VEGFR3-short, which has a shorter
cytoplasmic tail (Pajusola et al., 1993). VEGF-C/-D binding, via co-receptor NRP2
(Yuan et al., 2002), activates VEGFR3 to promote lymphatic vasculature development. It
has previously been shown that VEGFC/VEGFR3 signaling is essential for proliferation
and migration of lymphatic endothelial cells (LECs) in vitro (Jeltsch et al., 1997). It is
also true in vivo, as Chy mice (heterozygous for VEGFR3 kinase domain mutation)
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display lymphedema, swelling caused by lymphatic vasculature defects (Karkkainen et
al., 2001).
Upon VEGF-C/-D binding, VEGFR3 undergoes homo-dimerization with an adjacent
receptor that triggers trans-phosphorylation at Tyr1068 residue located in the kinase
domain (Fig. 7). Mutagenesis analysis confirmed that this tyrosine residue is important
for regulating kinase activity (Salameh et al., 2005), thus making it the site of “firstphase” autophosphorylation. The following phosphorylation can take place at six other
tyrosine residues (Tyr1063, Tyr1230, Tyr1231, Tyr1265, Tyr1337 and Tyr1363) on the receptor.
Besides, integrins can induce VEGFR3 phosphorylation at other different tyrosine
residues, which is independent of VEGF-C/-D binding and receptor kinase activity
(Galvagni et al., 2010).
VEGFC
VEGFC

S-S

S-S

Plasma membrane

CRKI/II
Tyr1068

SHC – GRB2 complex

PI3K
PLCγ

Figure 7. VEGFC-induced VEGFR3 signaling cascades. The disulfide (S-S) bond represents the fifth
immunoglobulin-like (Ig-like) domain of VEGFR3, which is proteolytically processed.
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Most of those VEGFR3 phosphorylation sites have been studied in vitro (Mäkinen et al.,
2001; Wang et al., 2004). In summary, phosphorylated Tyr1063 interacts with the adaptor
protein, CRKI/II. This in turn activates MKK4, which acts via the c-Jun N-terminal
kinase (JNK) pathway to promote cell survival. Other phosphotyrosines are responsible
for generating docking sites for recruitment of SH2/ PTB containing proteins such as
SHC-GRB2 complex, PLC-gamma and PI3K kinase that lead to signaling of ERK1/2
(cell proliferation) or AKT (cell survival) pathways. The first pathway, via SHC-GRB2
complex, activates c-Raf-1, which facilitates subsequent phosphorylation/ activation of
downstream kinases MEK and ERK1/2, a cell proliferation regulator. In the second
pathway, activated VEGFR3 recruits and phosphorylates PLC-gamma to catalyze
phosphatidylinositol (4,5)-bisphosphate (PIP2) hydrolysis into inositol 1,4,5-triphosphate
(IP3) and diacylglycerol (DAG). The latter product induces phosphorylation of protein
kinase C (PKC), which also leads to activation of c-Raf-1 for ERK1/2 proliferation
signaling. The third pathway, PI3K cascade, is important for lymphatic development as it
regulates cell survival/ migration. Recruitment of PI3K activates this kinase to
phosphorylate PIP2 into phosphatidylinositol (3,4,5)-triphosphate (PIP3). Thus, activated
PIP3 binds and activates AKT, a regulator for cell survival. Through these signaling
cascades, VEGFR3 facilitates LECs migration towards VEGFC-generating sources that
contribute to the formation and remodeling of the lymphatic vasculature.
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1.3.3

VEGFC processing and activity

VEGFC is an indispensible growth factor for LEC proliferation and survival, as well as
the development of the entire lymphatic vasculature. An important difference in the
structure of VEGFC, unlike the other VEGF members (except for VEGFD), is the
presence of additional N-terminal and C-terminal peptides flanking the VHD, which
requires proteolytic processing during VEGFC synthesis. The previous in vitro VEGFC
processing model indicates processed VEGFC can activate both angiogenic receptor
(VEGFR2) and lymphatic receptor (VEGFR3); nevertheless, VEGFC in vivo signaling is
lymphatic-specific (Joukov et al., 1997). This model does not address how VEGFC
processing regulates it receptor affinity and activity in vivo. According to the in vitro
VEGFC processing model, the ligand is initially synthesized as 61kDa “Prepropeptide”
containing signal peptide, N-terminal peptide (NT), VHD and C-terminal peptide (CT);
then dimerizes through disulfide bonds between monomers’ flanking peptides (NT and
CT), plus non-covalent interactions between two VHDs to give rise to 58kDa
“Propeptide” dimer. The CT is cleaved off from propeptide monomers intracellularly by
Furin and other protein convertases (Siegfried et al., 2003) and the partially processed
ligands exit resident cells as "Pro-VEGFC".
Once Pro-VEGFC reaches to the extracellular environment, another proteolytic cleavage
occurs at the N-termini of each monomer to completely remove both NT and CT, thus
resulting in 21kDa active form of VEGFC that activates both VEGFR2 and VEGFR3 in
vitro. However, it is not yet clearly known the mechanism by which VEGFC is activated
in vivo. Recently, Jeltsch et al. suggested that VEGFC activity in vitro is tightly regulated
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by the activity of a secreted protein, CCBE1, and a metalloproteinase, ADAMTS3
(Jeltsch et al., 2014).
On the other hand, the VEGFC homolog, VEGFD, also undergoes proteolytic processing
to become active (McColl et al., 2007). Since the loss of VEGFD does not result in
lethality in mice, it is not yet known how VEGFD contributes to the lymphatic
vasculature in vivo.
Furin / Protein covertases (PC5/ PC7)

Prepro-C

VHD$
S&S$

S&S$
VHD$

Intracellular environment

ADAMTS3

CCBE1

Extracellular environment

VHD$

Pro-C

S&S$

S&S$
VHD$
VHD$
S&S$

VHD$

S&S$

Figure 8. Schematic of VEGFC proteolytic processing events.
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1.4

Collagen and calcium-binding epidermal growth factor domain -1 (CCBE1)

role in lymphangiogenesis
1.4.1

The Hennekam’s syndrome and the secreted protein CCBE1

Hennekam’s syndrome is a rare human autosomal recessive disorder characterized by
malformation of the lymphatic vasculature. There are currently about 50 cases of
Hennekam’s syndrome reported worldwide. The main characteristics of Hennekam’s
syndrome are lymphatic vessels that are abnormally expanded (lymphangiectasia), tissue
swelling caused by lymph trapping (lymphedema), and features of mental retardation
(Fig. 9). Lymphangiectasia often prevents the flow of lymph fluid, causing the lymphatic
vessels to rupture. The ruptured vessels can lead to accumulation of lymph fluid, which
contributes to lymphedema. The lymphedema in Hennekam’s syndrome is often
noticeable at birth and usually affects the face and limbs. Severely affected infants may
have extensive swelling caused by fluid accumulation before birth. Hennekam patients
often also have intellectual disabilities that range from mild to severe. In addition to those
features, other abnormalities found in individuals with Hennekam’s syndrome include
growth delay, respiratory problems, anemia, and so on. The signs and symptoms of
Hennekam’s syndrome vary widely among affected individuals, even those within the
same family. Life expectancy depends on the severity of the condition and can vary from
death in childhood to survival into adulthood.
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Figure 9. Examples of Hennekam patients (adapted
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2009).
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1.4.2

The potential role of CCBE1 in lymphangiogenesis

CCBE1 is a secreted protein that is 407AA, including a N-terminal calcium-binding
EGF-like domain and a C-terminal collagen-like assembly of GPP repeats. CCBE1 was
first described in zebrafish as an indispensible factor for embryonic lymphangiogenesis
as homozygous mutation of this protein leads to lack of parachordal lymphangioblasts
and lymphatic vessels (Hogan et al., 2009; Küchler et al., 2006). Homozygous Ccbe1deficient mice fails to form lymphatic vessels from E13.5 onwards (Yang et al., 2012;
Oliver, 2004; Bos et al., 2011), thus leading to lymphedema and LEC progenitors
impaired migration from CV.
Despite its identical loss-of-function phenotype to mice lacking of the lymphangiogenic
factor VEGFC, CCBE1 was initially proposed to be independent of VEGFC/ VEGFR3
pathway by Bos et al. (2011). However, in 2014, Le Guen et al. reported that zebrafish
CCBE1 regulates VEGFC/ VEGFR3-induced embryonic lymphangiogenesis using
immunofluorescence visualization of phosphorylated ERK in the posterior cardinal vein
(Le Guen et al., 2014). Interestingly, in this report, CCBE1 was suggested to be involved
in the post-translational activation of VEGFC, specifically the proteolytic cleavage at the
N-terminus of Pro-VEGFC ligand. As CCBE1 is not a protease, the question of which
protease is responsible for processing VEGFC’s N-terminus becomes intriguing. Jeltsch
et al. proposed that the metalloproteinase ADAMTS3 is the potential candidate that
cleaves VEGFC in vitro (Jeltsch et al., 2014). Nevertheless, a clear molecular
understanding of these events has not yet emerged because of the difficulties in following
VEGFC proteolysis, assessing its role in LEC responses ex vivo and in vivo, and lack of
evidences supporting a role of ADAMTS3 in lymphangiogenesis. The former is due to
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the fact that many studies have used VEGFR3 ectodomain pull-down approach, which is
biased toward detection of VEGFR3-binding VEGFC proteins, and limits to the role of
cell-surface-associated VEGFC activation. The latter, i.e. if ADAMT3 had an
indispensable role in lymphangiogenesis in vivo, was not yet known at the beginning of
this thesis. As a result, this thesis utilizes different approaches to avoid such bias and
limitations, while addressing this question.
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1.5

The A Disintegrin and Metalloproteinase with Thrombospondin motifs

(ADAMTS) family and ADAMTS3
1.5.1

The ADAMTS family

The human ADAMTS family consists of 19 zinc-dependent metalloproteinases that have
various roles in the regulation of tissue morphogenesis/ remodeling, inflammation and
angiogenesis. In general, genetic mutations in certain ADAMTS family members are the
causes of inherited genetic disorders, whereas defects in expressing others are linked to
arthritis, cancer and other cardiovascular diseases (reviewed in Kelwick et al., 2015).
The basic structure of ADAMTSs is organized into a pro-domain, a catalytic domain, and
an ancillary domain. The pro-domain of ADAMTSs not only maintains latency of proADAMTSs, but also assures proper enzyme folding. It has been reported that the prodomain is removed at R/KXnR/K sites by furin and furin-like pro-protein convertases
(PPCs) (Wang et al., 2004; Longpre et al., 2009). Moreover, the catalytic domain
consists of the metalloproteinase domain, in which three histidine residues coordinate a
Zn2+ ion that determines the enzyme activity (Gomis-Ruth, 2009), and the disintegrin-like
domain. The crystal structure for ADAMTS1, ADAMTS4, and ADAMTS5 revealed that
the

disintegrin-like

domain

is

a

cysteine-rich

region

stacking

against

the

metalloproteinase site, thus making it part of the catalytic domain (Gerhardt et al., 2007;
Mosyak et al., 2008). Furthermore, the carboxyl-terminal ancillary domains of
ADAMTSs have been suggested to determine enzyme localization and substrate
specificity. The ancillary domain in ADAMTS enzymes contains a thrombospondin 1like repeat (TSP1), followed by a cysteine-rich region and a variable cysteine-free spacer
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region, and finally a variable number of TSP1 domains, except for ADAMTS4 that has
none.

Figure 11. Structure of ADAMTS family members (adapted from Kelwick et al., 2015).
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1.5.2

The ADAMTS functional group in lymphangiogenesis

The members of ADAMTS family can be sub-grouped on the basis of their known
substrates: the aggrecanases or proteoglycanases (ADAMTS1, 4, 5, 8, 9, 15 and 20), the
cartilage oligometric matrix protein-cleaving enzymes (ADAMTS7 and 12), the vonWillebrand Factor proteinase (ADAMTS13), and the procollagen N-propeptidases
(ADAMTS2, 3 and 14). Other ADAMTSs (like ADAMTS6, 10, 16, 17, 18, and 19), the
substrate of which is unknown, remain uncategorized. Most of the ADAMTS proteases
have not been reported to participate in lymphangiogenesis, except for ADAMTS3 that
belongs to the procollagen N-propeptidases subgroup (Jeltsch et al., 2014).
ADAMTS2, 3 and 14 have been identified to be the major proteases involved in collagen
fibril maturation. Ehler-Danlos’s syndrome (EDS) type VIIc is an inherited connective
tissue disorder, which is caused by a defect in the processing and maturation of collagen.
As maturation of collagen fibrils is essential to assure tissue physical strength and
morphologies, patients with EDS type VIIc present several phenotypes including severe
skin fragility, depressed nasal bridges, micrognathia and short stature (Cabral et al.,
2005). In the context of EDS type VIIc, ADAMTS-2 is the most important pro-collagen
peptidase. Several mutations in ADAMTS-2 have been described and are associated with
EDS type VIIc (Colige et al., 2004). The Adamts2-/- mice, despite surviving to birth, show
defects in procollagen processing, abnormal lungs and fragile skin (Le Goff et al., 2006).
This demonstrates that ADAMTS3 and 14 are not sufficient to compensate for the loss of
ADAMTS2 in the skin. However, at the beginning of this thesis, the phenotype that is
caused by loss of the other two members, particularly ADAMTS3 had not been
identified. Therefore, the study of ADAMTS3 activity and functions in this thesis would
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provide a novel insight into the importance of this protein, which has not been
appreciated in the past.
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1.6

Project hypothesis and thesis aims

Hypothesis: Proteolytic activation by ADAMTS3 defines distinct mechanisms of
lymphangiogenesis mediated by VEGFC and VEGFD.
Recent studies have implicated CCBE1 and ADAMTS3 in the regulation of VEGFC
processing, and generated a model of lymphangiogenesis in which VEGFR3-bound
VEGFC is cleaved by CCBE1 and ADAMTS3 during receptor activation (Jetlsch et al.,
2014). These studies have linked CCBE1 and ADAMTS3 to VEGFC function; but
limitations in the biochemical analysis of VEGFC and VEGFD proteolytic processing, a
lack of clear correlation between in vitro and in vivo studies, and lack of in vivo evidence
for the role of ADAMTS3 have limited the understanding of this complex
lymphangiogenic process. In addition, the structures of VEGFC and VEGFD are distinct
from those of other VEGF members, in which they contain N-terminal and C-terminal
domains that are proteolytically cleaved. The proteolytic processing of VEGFC and
VEGFD is thought to regulate lymphatic vessel growth, but precisely how this processing
is achieved and controlled in vivo has not been clear. In this thesis, an array of novel
biochemical, cellular and mouse genetic approaches will be used to dissect and
understand the relationships between CCBE1, ADAMTS3 and the lymphangiogenic
factors VEGFC and VEGFD:

1.

To biochemically follow VEGFC and VEGFD proteolytic processing by
inserting an epitope (FLAG) tag into the mature forms of these proteins
that does not interfere with proteolysis or VEGFR3 activation.
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2.

To test the role of ADAMTS3 in VEGFC and VEGFD processing ex vivo
using CRISPR/Cas9 genome editing to mutate the ADAMTS3 gene in
HEK293 cells.

3.

To determine whether and to what extent these biochemical and ex vivo
cellular findings predict in vivo lymphangiogenic responses by:
a.

Examining

lymphatic

development

in

ADAMTS3-deficient

embryos.
b.

Analyzing the lymphangiogenic responses induced by either
VEGFC or VEGFD in adult CCBE1-deficient mice.

Predictions:
The hypothesis supports a mechanism in which CCBE1 functions as an activator of the
ADAMTS3 protease that cleaves the N-terminus of VEGFC. N-terminal cleavage of
VEGFC by CCBE1 and ADAMTS3 is independent of the VEGFR3 receptor, but is
required for VEGFC to stimulate VEGFR3 signaling. Consistent with this molecular
model, embryonic ADAMTS3 deficiency should result in a complete loss of lymphatic
development in mice, a phenotype also observed with loss of either CCBE1 or VEGFC.
In contrast, it is expected that VEGFD processing is not regulated by either CCBE1 or
ADAMTS3 in vitro, and CCBE1-deficient animals exhibit normal lymphangiogenic
responses to VEGFD in vivo. Thus, these studies would demonstrate distinct mechanisms
of proteolytic activation for VEGFC and VEGFD that help explain their distinct roles in
prenatal and postnatal lymphatic vascular growth.
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CHAPTER TWO
Materials and Methods

Cell culture
HEK293T cell line (Invitrogen) and its derivatives (e.g. CRIPSR/Cas9 engineered
HEK293T cells) were maintained in DMEM with 10% FBS (Corning #35-010-CV) and
100 µg/mL Penicillin-Streptomycin (Invitrogen #15070063). All cell cultures were grown
at 37oC and 5% CO2 incubators.
Generation of epitope-tagged VEGFC, CCBE1, and ADAMTS3 proteins
Full-length human cDNAs for VEGFC, VEGFD, CCBE1, and ADAMTS3 were obtained
from GE Dharmacon (Lafayette, CO). Epitope-tagged cDNAs were generated through
PCR amplification using primers containing in-frame V5, Flag, or HA tags. All final
constructs were confirmed by nucleotide sequencing. Primers used are as follow:
CCBE1-V5
Forward - TCT AGA TCT GCT TCC CTG ATG GTG CCG
Reverse - AAG CGG CCG CTT AGG TGC TAT CCA GGC CCA GCA GCG GGT
TCG GGA TCG GCT TGC CTG GGT AGA AGT CTC TGG GGG CTC

CCBE11-175-V5
Forward - TCT AGA TCT GCT TCC CTG ATG GTG CCG
Reverse - AAG CGG CCG CTT AAT GAT GAT GAT GGT GGT GGG TGC TAT
CCA GGC CCA GCA GCG GGT TCG GGA TCG GCT TGC CGG ATTG GAA
GTA CAG GTT CTC GGT ACA TGT CTT
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VEGFC-V5
Forward - TCT GGA TCC GGT ACC CGG TCC TTC CAC CAT GCA CTT GCT
GGG
Reverse - AAG CGG CCG CTT AGG TGC TAT CCA GGC CCA GCA GCG GGT
TCG GGA TCG GCT TGC CGG CGC TCA TTT GTG G

VEGFCΔC-flag-V5
Forward - TCT GGA TCC GGT ACC CGG TCC TTC CAC CAT GCA CTT GCT
GGG
Reverse - AAG CGG CCG CTT AGG TGC TAT CCA GGC CCA GCA GCG GGT
TCG GGA TCG GCT TGC CCT TGT CAT CGT CGT CCT TGT AGT CAC GTC
TAA TAA TGG AAT GAA CTT GTC

VEGFCΔNΔC
Forward - TAG GAT CCG CCA CCA TGG AGA CAG ACA CAC TCC TGC TAT
GGG TAC TGC TGC TCT GGG TTC CAG GTT CCA CTG GTA CAG AAG AGA
CTA TAA AAT TTG C
Reverse - AAG CGG CCG CTT AAC GTC TAA TAA TGG AAT GAA CTT GTC

VEGFC-VHD-flag
Reverse (of the N-terminal portion) – GGA TCC CTT GTC ATC GTC GTC CTT
GTA GTC AAC TTG TCT GTA AAC ATC C
Forward (of the C-terminal portion) - GGA TCC CAT TCC ATT ATT AGA CGT
TCC

VEGFD-VHD-flag
Forward - CCA TAC TCA ATT ATC AGC AGC TCC ATC CAG ATC CCT GAA
G
Reverse - C TTC AGG GAT CTG GAT GGA GCT GCT GAT AAT TGA GTA
TGG
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ADAMTS3-V5
Forward - TAG GAT CCG CCA CCA TGG TTC TCC TGT CAC TTT G
Reverse - AAG CGG CCG CTC AGG TGC TAT CCA GGC CCA GCA GCG GGT
TCG GGA TCG GCT TGC CTC TTT CTA AGG TGG A

ADAMTS3-HA
Forward - TAG GAT CCG CCA CCA TGG TTC TCC TGT CAC TTT G
Reverse - AAG CGG CCG CTC AAG CGT AAT CTG GAA CAT CGT ATG GGT
ATC TTT CTA AGG TGG A

ADAMTS3ΔCT-HA
Forward - TAG GAT CCG CCA CCA TGG TTC TCC TGT CAC TTT G
Reverse - AAG CGG CCG CTC AAG CGT AAT CTG GAA CAT CGT ATG GGT
AAC AAG GAG GCA GTT G

ADAMTS3Δ3TSP-HA
Forward - TAG GAT CCG CCA CCA TGG TTC TCC TGT CAC TTT G
Reverse - AAG CGG CCG CTC AAG CGT AAT CTG GAA CAT CGT ATG GGT
AAT GGA TGA TGT ACT T

ADAMTS3ΔSpacer-HA
Forward - TAG GAT CCG CCA CCA TGG TTC TCC TGT CAC TTT G
Reverse - AAG CGG CCG CTC AAG CGT AAT CTG GAA CAT CGT ATG GGT
AGC AGT GGG AAT TAT CTC CTC

ADAMTS3ΔCys-tich-HA
Forward - TAG GAT CCG CCA CCA TGG TTC TCC TGT CAC TTT G
Reverse - AAG CGG CCG CTC AAG CGT AAT CTG GAA CAT CGT ATG GGT
AGC ATT CTT CTG TGT TAC AAA
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ADAMTS3Δ4TSP-HA
Forward - TAG GAT CCG CCA CCA TGG TTC TCC TGT CAC TTT G
Reverse - AAG CGG CCG CTC AAG CGT AAT CTG GAA CAT CGT ATG GGT
AAT TGC CAT CTT GTT TTT GCT

ADAMTS3ΔDisintegrin-HA
Forward - TAG GAT CCG CCA CCA TGG TTC TCC TGT CAC TTT G
Reverse - AAG CGG CCG CTC AAG CGT AAT CTG GAA CAT CGT ATG GGT
AAA GGA GAC AGT CAT AGG AAT

Point mutations in CCBE1 and VEGFC were generated using the QuikChange II SiteDirected Mutagenesis Kit (Agilent Technologies #200523). The procedure was carried
out according to manufacturers’ guidelines. All final constructs were confirmed by
nucleotide sequencing. Mutagenesis primers used are as follow:

VEGFC-RR226,227SS
Forward - CAA GTT CAT TCC ATT ATT TCC TCC TCC CTG CCA GCA ACG
TTA
Reverse - TAA CGT TGC TGG CAG GGA GGA GGA AAT AAT GGA ATG
AAC TTG

VEGFC-LTTTF
Mutagenesis step 1:
Forward - ACT ATA AAA TTT GCT GCA ACG TTC TAT AAT ACA GAG ATC
TTG LEC
Reverse - CAA GAT CTC TGT ATT ATA GAA CGT TGC AGC AAA TTT TAT
AGT
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Mutagenesis step 2
Forward - ACA GAA GAG ACT ATA AAA TTG ACT ACA ACG TTC TAT AAT
ACA GAG
Reverse - CTC TGT ATT ATA GAA CGT TGT AGT CAA TTT TAT AGT CTC
TTC TGT

CCBE1D170E
Forward - CAT CCG GGA AGA TGA AGG GAA GAC ATG TAC CCG GGG
AGA CAA ATA TCC
Reverse - GTA GGC CCT TCT ACT TCC CTT CTG TAC ATG GGC CCC TCT
GTT TAT AGG

Protein expression and characterization
Epitope-tagged cDNA constructs were cloned into pcDNA 3.1+ and transfected into
wild-type HEK293T cells or mutant HEK 293T lines where indicated. Cells were plated
at density of 3x105 cells/10 cm2 and transfected using Lipofectamine 2000 in 1:6 ratio
(Invitrogen #11668019). Unless otherwise indicated, conditioned media were collected
72 hours after transfection. Conditioned supernatants were mixed at a 1:1 ratio unless
otherwise indicated and incubated for 18 hours at 37oC prior to analysis. Untransfected
HEK293T conditioned media (CM) was collected and used as control supernatant.

Western Blotting
Supernatant samples from CM mixings were loaded and run on SDS–polyacrylamide gel
electrophoresis (PAGE) 12% gradient gel (BioRad, Carlsbad, CA) as soon as mixing was
complete, then transferred onto PVDF membrane. Whole-cell protein extracts were
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prepared by addition of RIPA lysis buffer (25 mM Tris.HCl pH 7.6, 150 mM NaCl, 1%
NP-40, 1% sodium deoxycholate, 0.1% SDS, and complete protease inhibitors (Roche
#4693159001). Lysates were separated by SDS–polyacrylamide gel electrophoresis
(PAGE) on a 4% to 12% gradient gel and transferred to PVDF membrane. Western
blotting was probed with anti-V5-HRP (1:5000, Invitrogen #46-0708), anti-Flag-HRP
(1:2500, Sigma #A8592-1MG), and anti-HA (1:10000, Biolegend #MMS-101P-500)
antibodies. All HRP-conjugated antibody blots were developed using ECL reagent
(Invitrogen). HRP-conjugated goat anti-mouse or anti-rabbit IgG antibody (1:10000;
Jackson Immunoresearch) was used as secondary antibody for detection.

Post-translational modification of CCBE1
CCBE1-V5 was transfected into HEK293T cells and collected after 72 hours.
Supernatants of CCBE1-V5 were treated with Heparinase (Sigma #H2519),
Chondroitinase (Sigma #C3667), PNGase F (Sigma #P7367), and O-glycosidase (Sigma
# G1163) for 1 hour at 37oC. Final products were analyzed by Western blotting.

Phospho-VEGFR3 ELISA assay
Neonatal lymphatic endothelial cells were obtained from Lonza (#CC-2543) and used
between passage 6 and 8. LECs were plated on 6-well plates (density = 3x105 cells/10
cm2), and starved with 900 µl starving media [EBM2 media (Lonza #CC-3156) + 0.1%
BSA (Sigma #A1595)] for 6 hours at 37oC. Serum starved LECs were treated with 100 µl
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of the indicated conditioned media for 15 minutes at 37oC. The media was then aspirated
and the cells washed three times with cold PBS before being lysed with 150 µl of
Phospho-VEGFR3 lysis buffer (1% NP-40 Alternative, 20 mM Tris (pH 8.0), 137 mM
NaCl, 10% glycerol, 2 mM EDTA, 1mM activated sodium orthovanadate, 10% protease
inhibitors). Samples were collected and the following steps were complied with
instructions in Human Phospho-VEGFR3 ELISA kit (R&D #DYC2724-5).

Immunoprecipitation
Conditioned supernatants were harvested (after 72h transfection) and mixed for 18 hours
at 4oC before adding anti-V5-tag magnetic beads (MBL #	
  M167-11). The magnetic beads
were then incubated with final mix for 6 hours at indicated conditions (4oC or 37oC or
addition of EDTA). Beads were washed three times using Optimem 1x (Invitrogen #	
  
31985062) and bound proteins then eluted in 4x sample buffer (Invitrogen #	
  NP0007) and
analyzed by Western blotting.

CRISPR/Cas9 generation of ADAMTS3-deficient and CCBE1-deficient HEK293T
cells
Guide RNAs (5’-CACCGTTGGTTGATAGCAGCCGCTC-3’) targeting the signal peptide
of ADAMTS3 were cloned into the pSpCas9 (BB)-2A-Puro (PX459) V2.0 plasmid
(Addgene). The resulting plasmids were then transfected into HEK293T cells on 6-well
plates using the FuGENE6 (Promega #E2691) reagent and standard protocols. The
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transfected cells were then selected by addition of puromycin to the media between 12
and 36 hours post-transfection, and the selected cells were then clonally diluted onto 96
well plates. After two weeks of growth, wells with single colonies were identified and
subsequently expanded. For each of these HEK293T clones, the targeted region of the
ADAMTS3 gene was then amplified by PCR, and individual PCR products were isolated
by TA cloning (T-easy vector, Invitrogen #A1380).

A sample of the amplified

ADAMTS3 alleles present in each cell line was obtained by sequencing at least 10
different TA-cloned PCR products from each line.
In the same approach as mentioned above, CCBE1-deficient HEK293T clones were
generated, selected, expanded, and extracted for sequencing.
CCBE1 gRNA (CRISPR): 5’- CACCGTCCACGTGTGTCCCAACGCC -3’

Plasmin activity assay
VEGFC-VHD-flag and VEGFD-VHD-flag were transfected into ADAMTS3-deficient
HEK293T cells, and collected supernatants after 72 hours. Supernatants CMs were
treated with plasmin (HTI #HCPM-0140) at 37oC, and final products were analyzed by
Western blotting.
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Mouse lines
Ccbe1 null and conditional alleles were generated and previously reported (Zou et al.,
2013). The Ccbe1 gene was disrupted in SV129 embryonic stem (ES) cells by replacing
the coding portion of exon 3 with a gene-trap cassette containing a splice acceptor IRESβ polyA and an FRT-flanked neomycin resistance cassette (L1L2_Bact_P). A conditional
allele was generated by replacing exon 3 with a loxP-flanked exon 3 cassette. Correctly
targeted ES cells were injected into blastocysts and chimeric offspring were crossed with
SV129 and C57Bl/6 mice. Prox1-GFP, Ccbe1 animals were generated by crossing Ccbe1
with Prox1-GFP animals (Choi et al., 2011). Adult VEGFC Knock-Out (KO) and
VEGFD KO mice have been previously described (Nurmi et al., 2015; Baldwin et al.,
2005). The Ub-CreERT2 allele was obtained from Jackson Labs (#70017). The Adamts3
targeted mice were obtained from Adamts3tm1a(KOMP)Wtsi,

clone ID EDP0660_2_C10

sperm from

the KOMP repository (http://www.komp.org). Adamts3 null mice generated by crossing
Adamts3tm1a(KOMP)Wtsi, clone ID EDP0660_2_C10 and EIIa-Cre animals (Jackson labs #003724).
Neonatal and adult deletions were induced by administration of tamoxifen. A total of 0.1
mL of 20 mg/mL tamoxifen in sunflower oil was injected intraperitoneally daily for 14
days to induce deletion in adult Ub-CreERT2;Ccbe1flox/lacZ mice. Adult animals were
maintained on tamoxifen chow for more than 6 weeks prior to in vivo studies to ensure a
high deficiency state.
The University of Pennsylvania Institutional Animal Care and Use Committee approved
all animal protocols.
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Whole-mount microscopy
Imaging of ear lymphatics was performed after manual splitting of the ear leaflets
performed after a one-hour incubation in PBS. For whole-mount immunostaining, ear
leaflets were fixed overnight in 4% paraformaldehyde at 4oC. Tissue was permeabilized
in TBS plus Triton X-100, and stained overnight with anti-LYVE1 (R&D) antibodies,
and detected using secondary antibody conjugated to Alexa-568.

Viral expression of VEGFC in vivo
Cutaneous adenoviral expression: 2 x 108 - 2 x 109 PFU of adeno-VEGFC or control
adenovirus expressing either VEGFB or GFP were injected subcutaneously in the dorsal
skin of adult mice. 1 x108 PFU of adeno-mCherry was co-injected to identify the site of
expression prior to skin harvest. After 48h, BrdU was injected intraperitoneally 24h prior
to harvest to label proliferating cells.
Muscular adeno-associated viral expression: AAV9 constructs containing murine fulllength VEGFC, VEGFCΔNΔC or VEGFD were used (Anisimov et al., 2009). 9-12 x 1010
viral particles mixed with AAV9-mCherry was injected into the left tibalis anterior and/or
gastrocnemius muscles. Muscles were harvested 4 weeks after injection for histologic
analysis of lymphatic growth.
The viruses were provided by the Alitalo lab (University of Helsinki, Finland) and also as
a kind gift from Dr. Calvin Kuo (Stanford University, Palo Alto, CA).
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Histologic analysis
Mouse embryos and tissues were fixed in 2% paraformaldehyde for 24hours, dehydrated
in 100% ethanol, and embedded in paraffin. Serial 6 µm-thick sections were subjected to
hematoxylin and eosin (H&E) or immuno-histochemical staining. Immunofluorescence
was performed with polyclonal anti-mouse antibodies for PROX1 (Abcam #76696), and
LYVE-1 (R&D #AF2125), VEGFR3 (R&D #AF743), PECAM (R&D #MAB3628),
FLK-1 (BD Biosciences #555307), K14 (Covance #PRB-155P) or BrdU (Abcam
#ab6326).
Images were acquired with a Nikon Eclipse 80i microscope using a 20x/0.50 or 40x/0.75
numeric aperture (NA) dry objective.

The peritoneal inflammatory assay
Experimental animals were injected with 25 µg LPS (Escherichia coli 0111:B4; SigmaAldrich) in 200µl PBS for the first two days, allowed mice to recover for the next two
days, and continued for four consecutive days with a daily dose of 12.5 µg LPS in 200µl
PBS. Necropsy was performed on day nine; diaphragms were fixed in 4% PFA overnight
in cold and stained for LYVE1 (R&D) using a standard whole mount protocol. Images
were acquired using AzioZoomV16 microscope equipped with Orca Flash 4 camera and
LYVE1 area was quantified using ImageJ. Brush painting of the LYVE1 lymphatic
vessels was used to improve the contrast and the accuracy of quantification.
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The full thickness excision assay
16-week C57Bl/6 mice (approximately 20g) were injected with Buprenorphine (0.5-1
mg/kg) analgesia and anesthetized using Isoflurane (5% Isoflurane in 1L/min Oxygen).
Once mice are anesthetized, they will be transferred to a nose cone with 1% Isoflurane
and 1L/min Oxygen. The pedal (paw pinch) reflex will be used to determine the depth of
anesthesia. Back hair was clipped off each mouse using clippers. Iodine was applied to
the rear dorsum to prevent injection during surgery and cleaned by alcohol pad. Blunttipped scissors and curved forceps were used to remove a 1.5cm x 1.5cm area of skin
down to but not including the muscle layer. Mice were daily observed after surgery and
harvested at indicated time. Newly healed skin samples were processed and analyzed by
immunohistochemistry using PROX1 (Abcam) and LYVE1 (R&D) antibodies. Highpower field images were acquired with a Nikon Eclipse 80i microscope (40 fields per
skin sample), and number of lymphatic (PROX1+ LYVE1+) vessels and PROX1+ nuclei
were counted.

Statistical Analysis
All error bars indicate standard error of the mean (SEM). Unpaired, two-tailed student’s
T-test was applied to all indicated samples. A P value less than 0.01 was considered
significant.
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CHAPTER THREE
CCBE1 drives N-terminal cleavage that is independent of both C-terminal cleavage
and VEGFR3 interaction capabilities of VEGFC
3.1

Rationale

Most previous studies of VEGFC and VEGFD proteolytic processing have been
performed using VEGFR3 ectodomain pull-down of metabolically labeled proteins to
identify the different species of these secreted growth factors. This approach has
successfully demonstrated post-translational proteolysis of these proteins, but detection
based on VEGFR3 binding may bias protein detection because VEGFC and VEGFD
proteins bind more weakly than processed proteins to VEGFR2 and VEGFR3 receptors.
VEGFC processing is believed to involve two distinct proteolytic events that combine to
release a central peptide that is homologous to VEGFA termed the VEGF homology
domain (VHD). To follow VEGFC processing in a direct and unbiased manner, we
introduced a FLAG epitope into the C-terminal end of the VEGFC-VHD immediately
adjacent to the well-characterized site of C-terminal cleavage. To further follow
proteolytic processing using VEGFC VHD-FLAG, we first generated a VEGFC VHDFLAG that also contains an HA tag fused in frame to the end of the VEGFC C-terminus
(CT). We could then study the relationship between VEGFC cleavage and its activity by
measuring the level of VEGFR3 phosphorylation and identifying the cleavage site. By
mutating specific amino acids within the cleavage site, we were able to manipulate
VEGFC N-terminal cleavage to answer the question how crucial the proteolytic
processing is for VEGFC activation.
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3.2

Detection of VEGFC processing in vitro

Immunoblot analysis for FLAG in the conditioned medium of HEK293 cells that express
VEGFC VHD-FLAG CT-HA (Fig. 12A) revealed a dominant ∼35 kDa band under
reduced conditions, consistent with a peptide containing the N-terminus (NT) and VHD
domains of VEGFC. Anti-FLAG immunostaining under non-reduced conditions revealed
a strong 58-60 kDa band (Fig. 12B). Anti-HA immunostaining of the same blot revealed
a 28 kDa band under reduced conditions, consistent with the isolated CT, and a 58-60
kDa band identical to that observed with anti-FLAG antibodies under non-reduced
conditions, indicating that the 58-60 kDa band most likely represents NT-VHD-FLAG
and CT-HA peptides bound together by disulfide bonds.

Figure 12. Expression of VEGFC VHD-FLAG in vitro. (A) Schematic of the VEGFC VHD-FLAG
protein in which a FLAG epitope is inserted in frame at the C terminal end of the VHD. Disulfide
bonds are predicted to link two full-length VEGFC VHD-FLAG molecules as shown below. (B)
Detection of VEGFC-VHD-FLAG with a C-terminal HA tag is shown under reduced and non-reduced
conditions using anti-FLAG (left) and anti-HA (right) antibodies. NT, amino terminus; VHD, VEGF
homology domain; CT, carboxyl terminus. The VEGFC VHD-FLAG construct was designed by Dr.
David Enis.
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3.3

CCBE1 full-length drives VEGFC N-terminal cleavage in a time-dependent

manner
To test the effect of CCBE1 on VEGFC processing, we incubated VEGFC VHD-FLAG
with CCBE1-V5 by mixing conditioned supernatants of HEK293T cells. Incubation of
VEGFC with CCBE1 resulted in the generation of a single 19-21 kDa protein containing
the VEGFC VHD at 370C but not 40C. This result was consistent with the notion that the
NT cleavage of VEGFC correlates with enzymatic activity, which is temperature
dependent. Timed analysis of mixed supernatants incubated at 370C for 0-18 hours
revealed progressive cleavage of VEGFC VHD-FLAG with complete processing by 18
hours (Fig. 13). In this assay, we were able not only to demonstrate CCBE1 facilitates
VEGFC processing at its NT, but also to design a standard protocol to study VEGFC
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Figure 13. Full length CCBE1 drives VEGFC proteolysis in vitro. (A) HEK293T conditioned media
containing VEGFC VHD-FLAG alone or VEGFCVHD- FLAG + CCBE1-V5 were incubated for 24
hours at 40C or 370C prior to detection of FLAG by immunoblot analysis. (B) Temporal analysis
reveals slow proteolysis of VEGFC in the presence of CCBE1. NT, amino terminus; VHD, VEGF
homology domain.
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Previous studies of VEGFC processing following protein expression by HEK293 and
other cell types have suggested that C-terminal cleavage after amino acid R227 occurs
prior to N-terminal cleavage and is highly efficient. To determine whether CCBE1-driven
NT cleavage requires prior CT cleavage, we examined the effect of CCBE1 on VEGFC
RR226/227SS-HA, a mutant in which the CT is not cleaved and the protein is C-terminally
tagged. VEGFC RR226/227SS-V5 (VEGFC CT uncleavable) was detected as a 58 kDa
protein that is consistent with a full length VEGFC protein containing the NT, VHD and
CT domains (Fig. 14). Following exposure to CCBE1, anti-V5 immunostaining identified
a 45kDa protein that is consistent with the VEGFC VHD and CT domains. These
findings demonstrate that CCBE1 drives N-terminal VEGFC proteolysis that is
independent of its processing at the CT cleavage site. Importantly, they also demonstrate
that CCBE1 regulation of VEGFC processing does not require interaction with LECs or
the VEGFR3 receptor conditions.
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Figure 14. N terminal cleavage of VEGFC is independent of C terminal cleavage. A VEGFC VHDFLAG protein containing a mutation that prevents C terminal cleavage (RR226-227SS) was incubated
with CCBE1-V5 or control conditioned medium for 24 hours. NT, amino terminus; VHD, VEGF
homology domain; CT, carboxyl terminus.
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3.4

The CCBE1 N-terminal domain does not support VEGFC processing

Since full length CCBE1 is difficult to express, previous studies have investigated
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Figure 15. A truncated form of CCBE1 lacking its C terminal collagen-like domain fails to drive
VEGFC cleavage. (A) Full length CCBE1-V5 was detected as a 70-100 kDa smear that was expressed
at lower levels than the 25 kDa CCBE1 175-V5. (B) VEGF VHD-FLAG was incubated with control
conditioned medium, conditioned medium containing full length CCBE1-V5 and conditioned medium
containing CCBE1 175-V5 for 24 hours prior to anti-FLAG immunoblot. NT, amino terminus; VHD,
VEGF homology domain.
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These studies reveal that the N-terminal domain of CCBE1 is not sufficient to drive
proteolytic cleavage of VEGFC, and suggest that previous studies using this peptide are
not likely to accurately reflect CCBE1 function [a conclusion supported by recent in vivo
structure function analysis of CCBE1 (Roukens et al., 2015)]. Possible roles for the
CCBE1 N-terminal domain in potentiating VEGFC proteolysis in vivo, e.g. localizing the
protein or interacting with other regulatory factors, require further studies to determine.
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Figure 16. Post-translational modification of CCBE1. CCBE1 is chondroitin sulfated and Nglycosylated. HEK293T conditioned supernatant generated by transfection with CCBE1-V5 plasmid
was treated with the indicated enzymes prior to western blot analysis. This assay was done by Dr.
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3.5

Activation of VEGFR3 by VEGFC requires N and C-terminal proteolysis

and is driven by CCBE1 in vitro
Previous studies of VEGFC processing have assessed its functional impact on VEGFC
activity by measuring binding to VEGFR3 ectodomain and common signaling endpoints
such as activation of ERK1/2 and AKT. These endpoints are not ideal because
unprocessed VEGFC may bind but not activate the receptor, and ERK and AKT are
promiscuous downstream signaling pathways that do not specifically measure VEGFR3
signaling. In contrast, our biochemical experiment suggested that HEK293T conditioned
medium is capable of promoting level of p-Akt and p-ERK without any introduction of
VEGFC (data not shown).
To better assess the functional significance of CCBE1 and VEGFC processing, we
therefore measured the phosphorylation level of VEGFR3 receptors in primary lymphatic
endothelial cells (LECs) using a phospho-VEGFR3 ELISA. The concept of this ELISA
assay is that once active VEGFC binds to its receptor, a number of tyrosine residues
including Tyr1068 on the C-tail domain of VEGFR3 are phosphorylated (mentioned in the
introduction section). These phosphorylated tyrosines can be detected by anti-phosphotyrosine-HRP antibody and quantified by colorimetric analysis to provide relatively
accurate concentration of phosphorylated VEGFR3 receptors. Exposure of primary
human LECs to VEGFC containing conditioned medium without added CCBE1 resulted
in little or no increase in the level of phospho-VEGFR3 as ligand concentration was
increased from 5 to 20 nM (as negative control). Exposure of LECs to VEGFC+CCBE1
mix resulted in a dose-dependent increase in the level of phosphorylated VEGFR3 that
fully reproduced the response to an engineered VEGFCΔNΔC protein (as positive control)
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(Fig. 17). This suggested that the increase in VEGFC ligand activity conferred by CCBE1
is likely to be due to CCBE1’s role in facilitating N-terminal proteolysis. Furthermore,
phospho-VEGFR3 has become a great tool to investigate relationships between VEGFC
structure and its activity.

Figure 17. Phospho-VEGFR3 was measured by ELISA. The LECs were under exposure to 5-20 nM
concentration of VEGFC that was incubated with conditioned medium from control HEK293T cells
(HEK293T CM) or CCBE1-V5 (CCBE1) or following exposure to VEGFC ΔNΔC-Fc. N=3 for each
concentration; error bars indicate SEM.

To directly test this mechanism, and better characterize it at the molecular level, we
isolated the single 19/21 kDa band of VEGFC VHD-FLAG generated by exposure to
CCBE1 and performed N-terminal Edman sequencing to identify the site of proteolytic
cleavage. The N-terminal sequence of this peptide was AHYNTEILK, indicating that
CCBE1 drives cleavage of VEGFC following the FAA sequence ending at amino acid
A111 (Fig. 18). With this information, investigating the cleavage site by generating point
mutations has become possible.
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Figure 18. Schematic representation of the VEGFC cleavage site facilitated by CCBE1.

Identification of the CCBE1- associated N-terminal cleavage site allowed us to next
generate a VEGFC mutant that cannot be cleaved at that site to directly test whether Nterminal proteolytic cleavage is required for VEGFC activity on LECs. Mutation of the
FAA-AHY sequence in VEGFC VHD-FLAG to LTT-TFY (VEGFC LTTTF) resulted in
a protein that was well expressed by HEK293T cells but was not N-terminally cleaved in
the presence of CCBE1 (Fig. 19).
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Figure 19. The VEGFC FAAAH109-113LTTTF mutant is not N terminally cleaved in the presence of
CCBE1. The five amino acids FAAAH were replaced by LTTTF using site-directed mutagenesis
approach. The mutant was uncleavable at its N-terminus. NT, amino terminus; VHD, VEGF
homology domain.
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Phospho-VEGFR3 ELISA showed that VEGFC-LTTTF (VEGFC NT uncleavable)
conferred no increase in phospho-VEGFR3 in primary LECs, with or without CCBE1
exposure. In contrast, wild-type VEGFC exhibited marked increases in phosphoVEGFR3 that were CCBE1-dependent (Fig. 20). These studies demonstrate that CCBE1driven proteolysis of VEGFC is required for the ligand to activate the VEGFR3 receptor,
and that the effect of CCBE1 on VEGFC activity is mediated by N-terminal cleavage.

Phospho-VEGFR3 (pg/ml)

NT uncleavable-flag + HEK293T CM

200

NT uncleavable-flag + CCBE1
VEGFC + HEK293T CM

150

VEGFC + CCBE1

100
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5 10 20 5 10 20 5 10 20 5 10 20
20
Ligand concentration (nM)
Figure 20. The N terminally uncleavable VEGFC (NT uncleavable) is unable to activate VEGFR3.
Phospho-VEGFR3 ELISA was performed as described using the indicated concentrations (5-20 nM)
of wild-type and NT uncleavable VEGFC, with and without CCBE1. N=3 for each concentration;
error bars indicate SEM.
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Similar to VEGFC NT uncleavable mutant, the CT uncleavable (VEGFC RR226/227SSV5) induced no increase in phospho-VEGFR3 regardless of CCBE1 presence (Fig. 21).
This result confirmed that VEGFC activation requires both NT and CT to be removed.
The proteolytic activation of VEGFC, therefore, must be specifically regulated at both Nand C-termini of the growth factor.
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Figure 21. C terminal cleavage of VEGFC is required for activation of VEGFR3 independent of N
terminal cleavage. LEC phospho-VEGFR3 was measured after exposure to wild-type VEGFC that is
tagged in its VHD (“VEGFC-VHD-FLAG”) or VEGFC with an uncleavable C terminus (the
RR226/227SS mutant) that is tagged at its carboxyl terminus (“VEGFC-CT-unclev V5”). N=3 for
each concentration; error bars indicate SEM.
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VEGFC activity towards VEGFR3 is reduced by increased length of the C

terminus.
In order to understand further the importance of C-terminal cleavage of VEGFC, we
generated a series of engineered VEGFC constructs (VEGFCΔC-FLAG-V5, VEGFCVHD-FLAG-ΔC, and VEGFC-LTTTF-VHD-FLAG-ΔC) to investigate how external
peptide sequences at the C-terminus might influence ligand activity (Fig. 22). The
number of amino acids at the C-terminus of each construct was labeled. These constructs
were expressed in HEK293T cells and conditioned media were collected for biochemical
analysis.
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Figure 22. Schematic of VEGFC mutant proteins with varying uncleavable C terminal amino acids
(with the number of amino acids C terminal of the VHD indicated). VEGFC-CT-unclev V5, the
RR226/227SS mutant; VEGFCΔC-FLAG-V5, VEGFC without a C terminus in which serial FLAG and
V5 epitopes have been fused in frame to the VHD; VEGFC-VHD -FLAG-ΔC, VEGFC without a C
terminus to which a FLAG epitope has been fused in frame to the VHD; VEGFC (LTTTF)-VHD FLAG-ΔC, VEGFC with a mutation blocking ADAMTS3 cleavage of the N terminus that also lacks a
C terminus and to which a FLAG epitope has been fused in frame to the VHD. NT, amino terminus;
VHD, VEGF homology domain; CT, carboxyl terminus.
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The phospho-VEGFR3 ELISA assay showed the level of phosphorylated VEGFR3 was
reduced when external peptide was added after the CT cleavage site of VEGFC (Fig. 23).
The 22 amino acids encoding Flag-V5 tags after the CT site of VEGFCΔC-FLAG-V5
reduced phospho-VEFGR3, compared to VEGFC-VHD-FLAG-ΔC construct. In
addition, the VEGFC (LTTTF)-VHD-FLAG-ΔC conferred no increase in phosphoVEGFR3 in primary LECs, confirming the requirement of N-terminal cleavage for
VEGFC activity. These findings demonstrated how tightly the NT and CT processing
must be regulated to assure the correct activation for VEGFC.
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Figure 23. The length of C-terminal peptide determines VEGFC affinity towards VEGFR3. (A)
Expression of the VEGFC mutant proteins described in by HEK293T cells and their cleavage
following incubation with ADAMTS3-containing conditioned medium. (B) The ability of the VEGFC
mutants to activate VEGFR3 was measured using a phospho-VEGFR3 ELISA. N=3 for each
concentration; error bars indicate SEM.
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thus the question to be address is whether lack of CCBE1 might inhibit VEGFC cleavage
in vitro. Here, we utilized the “Clustered regularly interspaced short palindromic repeats
ADAMTS3
CRISPR
CCBE1 G2-1-D1
(CRISPR)/ CRISPR-associated
proteins
(Cas) 9” (CRISPR/Cas
9) technique to create
WB: anti-FLAG

double strand breaks
55 in the signal peptide sequence of CCBE1. Sequencing mRNA

transcripts confirmed
35 disruption in the signal peptide of all CCBE1 alleles, thus hindering
VHD + NT
25

the protein expression (data not shown). Endogenous expression of VEGFC in VHD
CCBE1VEGFC (Flag-VHD)

+

+

+

+

+

+

+

ADAMTS3-HA (1:x); x =

-

30

90 270 540 1.6k -

+

+

+

+

deficient HEK293T does not undergo N-terminal processing within a 24-hour period,
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compared to HEK293T wild type (Fig. 24). Therefore, lack of CCBE1 inhibits VEGFC
N-terminal cleavage in vitro.
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Figure 24. CCBE1 is required for VEGFC processing in vitro. The level of endogenous VEGFC
processing was undetectable in the CCBE1-deficient cells within 24 hours of incubation, compared to
HEK293T wild types. NT, amino terminus; VHD, VEGF homology domain.
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3.8

Chapter discussion

A novel accomplishment in this study was that we were able to engineer VEGFC
construct into a robust biochemical tool to follow its proteolysis in vitro. Prior studies
have used either S35 radiolabelling or a single VEGFC VHD antibody to follow VEGFC
processing. The data have often been very hard to interpret (e.g. due to the requirement
for VEGFR3 ectodomain pull-down to interpret the radiolabelling experiments) and have
prevented direct detection of VEGFC proteolysis. Our introduction of VHD-tagged
VEGFC greatly contributed to solve any uncertainty, which had been raised due to
limitations of previous approaches like weak anti-VEGFC antibody or VEGFR3 pulldown. In combination with protein overexpression in HEK293T cells, the FLAG epitope
tag was able to provide clear and unambiguous detection of VEGFC ligand at different
stages during its proteolysis; VHD (19-21 kDa), NT+VHD (35 kDa), and NT+VHD+CT
(58-60 kDa). Phospho-VEGFR3 ELISA assay, as read-out for VEGFC activity, provided
reliable and consistent evidence that VEGFC remains inactive until both NT and CT are
precisely cleaved off. These results also suggested that VEGFC activity is mostly decided
by it proteolytic processing that occurs even in absence of VEGFR3 receptor or LECs.
For the first time, VEGFC has been shown to undergo proteolytic cleavages that are
independent of VEGFR3.
The biochemical data demonstrated a strong relationship between secreted CCBE1 and
lymphangiogenic factor VEGFC in vitro. Prior to this point, CCBE1 has been in a long
discussion whether its function involves in VEGFC proteolysis (Bos et al., 2011; Le
Guen et al., 2014). Our assays not only confirmed the requirement of CCBE1 in VEGFC
processing, but also displayed how CCBE1 regulated VEGFC activity by facilitating NT
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cleavage. We also revealed N-terminal domain of CCBE1 (CCBE 175) is not sufficient to
drive proteolytic cleavage of VEGFC that requires full-length chondroitin sulfated and Nglycosylated CCBE1.
Joukov et al. reported the inactive CT uncleavable mutant VEGFC (i.e. VEGFC
RR226/227SS) and detected two cleavage sites at N-terminus of VEGFC, which are after
either R102 or A111 amino acids in 1997. For almost 20 years, it has not been concluded
which of the two sites is responsible for VEGFC activation. Nevertheless, with our
FLAG tag, we were able to isolate the VEGFCΔNΔC protein, sequence, and determine the
CCBE1-faciliated cleavage site is at FAA111ê AHY. This novel finding also enabled us to
generate the NT uncleavable mutant of VEGFC (i.e. VEGFC LTTTF), which completely
inhibits VEGFC activity. This confirms the requirement of NT removal for VEGFC
activation. Furthermore, one of our challenges at this stage was to identify which protease
drives the NT cleavage. FAA is a specific recognition sequence for metalloproteinases,
especially ADAMTS2 and ADAMTS3 (Colige et al., 2005), which intrigued our next
investigation into ADAMTS3.
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CHAPTER FOUR
ADAMTS3 is an indispensible component of the VEGFC processing complex
4.1

Rationale

The finding of the precise location of the N-terminal cleavage site of VEGFC that is
facilitated by CCBE1 revealed proteolysis at FAAê AHYN, a sequence resembling that at
which collagen is processed by the ADAMTS2 and ADAMTS3 proteases (Colige et al.,
2005). This result is consistent with a previous report implicating ADAMTS3 in CCBE1mediated VEGFC processing by HEK293 cells (Jeltsch et al., 2014). It is, therefore,
inevitable to investigate the role of ADAMTS3 in the context of VEGFC proteolysis.
From the time of its identification, ADAMTS3 has not yet been studied intensively both
in vitro and in vivo. In order to understand this protein, we utilize CRISPR/ Cas9
technique to modify the signal peptide sequence of ADAMTS3, thus shutting the protein
expression in HEK293T cells. This technique generated a novel biochemical tool that
provides an ADAMTS3-free in vitro environment. With this tool, we could investigate
not only the functional activity, but also structural features of ADAMTS3 in vitro that
ultimately provided supporting evidences for existence of the VEGFC processing
complex.
On the other hand, our preliminary data suggested the proteolytic regulation of VEGFC
and its homolog VEGFD are potentially different. The biochemical comparison between
the two lymphangiogenic factors is also discussed in this chapter, which strongly
demonstrates evidence for distinct mechanisms of proteolytic activation between VEGFC
and VEGFD.
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4.2

EDTA blocks VEGFC processing

The metalloproteinase ADAMTS3 is a cation-dependent protease, activity of which could
be blocked by addition of EDTA. Addition of EDTA at 4 mM and 8 mM concentration to
mixed media containing both VEGFC and CCBE1 blocked the N-terminal cleavage of
VEGFC after 18 hours of incubation (Fig. 25). This finding was consistent with
metalloprotease activity, which requires Zn2+ to switch on the active site from its
precursor form. However, this result could only illustrate VEGFC processing requires
cations but it was not conclusive enough to state that ADAMTS3 is inactive. It is known
that the EGF-like domains of CCBE1 are also predicted to bind calcium and the result
might therefore reflect inactivation of CCBE1 function rather than inactivation of the
candidate protease. We, therefore, investigated the effect of ADAMTS3 deficiency on
VEGFC processing in the context of HEK293T cells.

Figure 25. Addition of EDTA reveals that CCBE1-dependent VEGFC proteolysis is cation
dependent. VEGFC could only be processed in the presence of CCBE1; however, this cleavage is
blocked at the concentrations of 4mM and 8mM EDTA that depletes free cations. NT, amino
terminus; VHD, VEGF homology domain.
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4.3

Deletion of ADAMTS3 eliminates VEGFC processing in HEK293T cells

To overcome the concern of unspecificity and more definitively test the requirement for
ADAMTS3, we next used CRISPR-Cas9 technique (Perez-Pinera et al., 2013) to mutate
the sequence in the ADAMTS3 gene that encodes the protease’s signal peptide in
HEK293T cells (Fig. 26A). Analysis of HEK293T clonal populations generated after
transfection with a plasmid-encoding guide RNAs targeting this sequence and Cas9
revealed that HEK293T cells are triploid for the ADAMTS3 gene (consistent with prior
cytogenetic studies Bylund et al., 2004). HEK293T clones with mutations predicted to
disable 1, 2 or 3 ADAMTS3 alleles were identified. Analysis of VEGFC VHD-FLAG
processing following expression of VEGFC and CCBE1 in ADAMTS3 mutant
HEK293T cell clones revealed complete processing in cells with 3 copies, partial
processing in cells with 1 or 2 copies, and a total loss of processing in cells with no wild
type ADAMTS3 alleles (Fig. 26B). Thus progressive loss of ADAMTS3 alleles resulted
in a dose-dependent reduction in CCBE1-driven VEGFC proteolysis. The ADAMTS3deficient cell line has become a great tool for investigating the function of ADAMTS3
since it provides an ADAMTS3-free environment. This loss-of-function study suggested
ADAMTS3 is required for VEGFC processing in vitro; therefore, the next study would
be to examine whether ADAMTS3 directly mediates N-terminal cleavage of VEGFC.
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Figure 26. ADAMTS3 is required for N terminal VEGFC proteolysis in HEK293T cells. (A) The
ADAMTS3 gene was disrupted in HEK293T cells using CRISPR/Cas9 to generate disabling
mutations in the sequence encoding the ADAMTS3 signal peptide. TSP, thrombospondin1 motif. (B)
Incubation of VEGFC VHD-FLAG and CCBE1-V5 generated by expression in HEK293T cell clones
with 3 (wt), 2 (4D5), 1 (4F9), or 0 (4C2) wild-type ADAMTS3 alleles revealed a dose-dependent loss
of VEGFC proteolysis with loss of ADAMTS3. NT, amino terminus; VHD, VEGF homology domain.
The ADAMTS3-deficient HEK293 cells were generated by Dr. David Enis and Jennifer Cohen.
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4.4

ADAMTS3 exclusively mediates the CCBE1-dependent VEGFC proteolytic

processing event in HEK293T cells
CRISPR-Cas9 genome editing is highly efficient, but may also result in off-target
mutations (according to Doudna and Charpentier, 2014). Thus, it is possible that clones
exhibiting greater loss of ADAMTS3 alleles may also harbor larger numbers of off-target
mutations, and that the loss of VEGFC processing may not be directly attributable to
mutations in ADAMTS3. To further test the causal role for ADAMTS3 in CCBE1directed VEGFC processing in vitro, we next expressed ADAMTS3-V5 in a HEK293T
cell clone that lacked all wild-type ADAMTS3 genes and did not support VEGFC
processing (clone 4C2). Expression of ADAMTS3-V5 revealed 2 bands of 220 and 240
kDa molecular weights in cell lysate and number of smaller bands in conditioned
supernatant, consistent with ADAMTS3 proteolysis in the extracellular environment (Fig.
27A). Expression of ADAMTS3-V5 rescued VEGFC processing in the ADAMTS3deficient HEK293T mutant cell line, and drove highly efficient VEGFC processing in the
absence of added CCBE1 (Fig. 27B). These genetic studies demonstrate that CCBE1driven VEGFC proteolytic processing is mediated exclusively by ADAMTS3 in HEK293
cells.
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Figure 27. ADAMTS3 mediates the CCBE1-dependent VEGFC proteolytic processing event. (A)
Expression of ADAMTS3-V5 in HEK293T cells revealed a 220/240 kDa doublet in cell lysate and a
number of smaller bands in conditioned supernatant consistent with extracellular proteolysis. (B)
Expression of ADAMTS3-V5 rescued proteolytic processing of VEGFC VHD-FLAG in ADAMTS3-//HEK293T cells. NT, amino terminus; VHD, VEGF homology domain.
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4.5

The catalytic metalloproteinase domain of ADAMTS3 is essential for

VEGFC processing
Being one of the first research groups to successfully engineer ADAMTS3 construct for
the purpose of in vitro studies, we utilized this novel tool to carry out structural studies on
the proteinase of interest. We generated a series of ADAMTS3 truncated mutants by
introducing a stop codon at the end of each sequential structural domain as
ADAMTS3ΔCT,

ADAMTS3Δ3TSP,

ADAMTS3ΔSpacer,

ADAMTS3ΔCys-rich,

and

ADAMTS3Δ4TSP respectively. A V5 tag was added at the C-terminus of each construct to
allow detecting protein expression and molecular weight. The expression of these
constructs showed discrete change in molecular weight according to their designs (Fig.
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Figure 28. Generation of a series of ADAMTS3 truncation mutations; namely ADAMTS3ΔCT,
ADAMTS3Δ3TSP (left), ADAMTS3ΔSpacer, ADAMTS3ΔCys-rich, and ADAMTS3Δ4TSP (right). All
constructs were secreted and harvested in the ADAMTS3-deficient HEK293T conditioned media.
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As these truncation mutants were successfully generated, we examined their activity in
cleaving VEGFC N-terminus compared to ADAMTS3 full-length control. The
biochemical results showed that all of these constructs were able to mediate VEGFC
proteolysis (Fig. 29). It is interesting because the C-terminal domains of ADAMTS3 have
been reported for substrate specificity in the context of pro-collagen maturation
(Fernandes et al., 2001); here our data demonstrated that those domains are not crucial
for cleaving VEGFC in vitro.
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Figure 29. ADAMTS3 truncation mutants were able to mediate VEGFC processing in vitro.
Engineered ADAMTS3 constructs [ADAMTS3ΔCT and ADAMTS3Δ3TSP (left panel);
ADAMTS3ΔSpacer, ADAMTS3ΔCys-rich, and ADAMTS3Δ4TSP (right panel)] were mixed with VEGFCVHD-FLAG for 18 hours at 37oC. All experimental steps were performed in the ADAMTS3-deficient
HEK293T conditioned media. NT, amino terminus; VHD, VEGF homology domain.

64

The biochemical data intrigued our study with the fact that even most of the protein was
removed; truncated ADAMTS3 constructs (as small as ADAMTS3Δ4TSP ~ 70kDa) were
still able to perform VEGFC processing. This strongly suggests ADAMTS3
metalloproteinase domain to play an indispensable role in cleaving VEGFC. In order to
test this idea, we continued to remove the disintegrin-like domain, which has been
discussed to be part of ADAMTS3 catalytic domain (Kelwick et al., 2015). Interestingly,
the mutant ADAMTS3ΔDisintegrin (~35kDa) could not process VEGFC-VHD-flag in mixed
conditioned media, compared to full-length ADAMTS3 (Fig. 30). This result confirmed
the importance of N-terminal ADAMTS3 catalytic domain to VEGFC proteolysis, rather
than the C-terminal domains that might only be crucial for pro-collagen maturation
(Colige et al., 2002).
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Figure 30. ADAMTS3ΔDisintegrin mutant was unable to process VEGFC. The truncated construct
ADAMTS3ΔDisintegrin could not cleave the NT (lane 3) that demonstrated lack of the disintegrin-like
domain might deactivate the proteinase. All experimental steps were performed in the ADAMTS3deficient HEK293T conditioned media. NT, amino terminus; VHD, VEGF homology domain.
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4.6

VEGFC, ADAMTS3, and CCBE1 interact in a single molecular complex –

the VEGFC processing complex
The biochemical studies suggested that VEGFC is cleaved by ADAMTS3 in a manner
that is tightly regulated by CCBE1. To better understand the molecular interactions that
govern this regulatory mechanism, we next took advantage of epitope-tagged proteins to
examine the physical association of these proteins by co-immunoprecipitation.
Consistent with previously reported studies (Jeltsch et al., 2014), VEGFC-VHD-FLAG

A

and CCBE1-V5 could not be co-precipitated from conditioned supernatant containing
both proteins (Fig. 31), indicating that VEGFC and CCBE1 do not directly interact.
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Figure 31. VEGFC does not directly bind CCBE1. VEGFC VHD-FLAG and CCBE1-V5 conditioned
media were mixed prior to immunoprecipitation with anti-V5 antibodies and immunoblot analysis
with anti-FLAG antibodies. Precipitated CCBE1-V5 is shown below.

In contrast, immunoprecipitation of CCBE1 from conditioned supernatant containing
ADAMTS3-HA and CCBE1-V5 resulted in efficient co-precipitation of ADAMTS3 (Fig.
32), indicating that ADAMTS3 and CCBE1 biochemically associate in a robust manner.
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B

We also investigated binding of ADAMTS3 towards other CCBE1 mutant constructs like
CCBE1 175 and CCBE1 D170E. ADAMTS3-HA could not be co-precipitated with
CCBE1 175-V5, consistent with our previous functional studies demonstrating an
inability of this truncated CCBE1 protein to drive VEGFC N-terminal cleavage.
Consistent with this result, CCBE1 D170E-V5, a CCBE1 protein with a mutation in the
N-terminal domain that causes loss of lymphatic growth in zebrafish embryos in vivo
(Hogan et al., 2009), retained strong interaction with ADAMTS3. Unexpectedly, a small
amount of ADAMTS3-HA could be co-precipitated with VEGFC-V5, suggesting that
VEGFC may pull down some ADAMTS3 in a manner that is dependent upon
endogenous HEK293T CCBE1 (Fig. 32).
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Figure 32. ADAMTS3 co-precipitates with full length but not N-terminal CCBE1. The indicated
conditioned media were mixed and CCBE1-V5 immunoprecipitated. Co-precipitated ADAMTS3-HA
is shown above and precipitated CCBE1-V5 proteins are shown below. This assay was done with the
help of Mei Chen.
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To test the possibility for the existence of a VEGFC-ADAMTS3-CCBE1 complex, we
next expressed VEGFC-V5, ADAMTS3-HA, and untagged CCBE1; then repeated the

IP: anti-V5
VEGFC co-immunoprecipitation experiments.
WB: anti-Flag

In the presence of added CCBE1,

VEGFC-V5 was able to efficiently pull down ADAMTS3-HA, which was not observed
in the control lane (Fig. 33). This finding is consistent with an idea that CCBE1 plays as a
co-factor to enhance the enzyme (ADAMTS3) – substrate (VEGFC) interaction.
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Figure 33. VEGFC co-precipitates with ADAMTS3 in a CCBE1-dependent manner. Conditioned
media containing ADAMTS3-HA and VEGFC-V5 were mixed alone and with media containing
untagged CCBE1 prior to anti-V5 immunoprecipitation. Addition of CCBE1 enabled VEGFC to pull
down ADAMTS3 (right lane) compared to control (left lane).
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Figure 34. ADAMTS3-CCBE1 release of VEGFC requires ADAMTS3 enzymatic activity. VEGFC
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and in the presence of EDTA to inhibit metalloprotease activity. Note that VEGFC was retained at
o
4 C and in the presence of EDTA, conditions that block ADAMTS3 enzymatic activity. This assay
was done with the help of Mei Chen.
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4.7

VEGFD processing is independent of both CCBE1 and ADAMTS3

VEGFC and VEGFD are homologous proteins that activate VEGFR3, and VEGFD
contains N and C terminal domains that are proteolytically processed in a manner
analogous to those in VEGFC (Stacker et al., 1999). As for VEGFC, a number of
different proteases have been implicated in the proteolytic processing of VEGFD
(McColl et al., 2003). Zebrafish genetic studies have recently suggested that VEGFD
function may be regulated by CCBE1 (Astin et al., 2014), but biochemical studies have
not revealed an effect of CCBE1 or ADAMTS3 on VEGFD processing (Jeltsch et al.,
2014). To directly compare the processing of these two lymphangiogenic growth factors,
we generated VEGFD VHD-FLAG in a manner analogous to that used to generate
VEGFC VHD-FLAG. VEGFD VHD-FLAG secreted from HEK293T cells appeared as 3
distinct 52, 33 and 19 kDa bands, consistent with proteins containing NT+VHD+CT,
VHD+CT and VHD domains respectively (Fig. 35). Moreover, addition of EDTA at the
concentrations of 4mM and 8mM did not change the expression pattern of VEGFD
showing that VEGFD could be processed by a non-metalloproteinase. This in vitro
observation is contrast to how EDTA affected VEGFC processing (Section 4.2)
suggesting VEGFC and VEGFD are proteolytically regulated in two different processing
pathways.
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Figure 35. VEGFD expression in HEK293T cells.55Addition of EDTA had no effect NTon VEGFD
VHD
processing. NT, amino terminus; VHD, VEGF homology domain; CT, carboxyl terminus. The
VEGFD VHD-FLAG construct was designed by Dr. David Enis.
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Figure 37. VEGFD VHD-FLAG proteolysis is independent of ADAMT3 and CCBE1. VEGFD
processing was not increased by incubation with conditioned medium containing CCBE1 (lane 2) or
ADAMTS3 (lane 3) or lack of ADAMTS3 (lane 4). NT, amino terminus; VHD, VEGF homology
domain; CT, carboxyl terminus.

Here, we demonstrated with supporting evidence that VEGFD processing is independent
of ADAMTS3/ CCBE1, thus suggesting a distinct mechanism for its proteolytic
activation from that of VEGFC.
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4.8

Plasmin greatly enhances VEGFD processing but not VEGFC processing in

HEK293T cells
VEGFD has been reported to be a substrate of plasmin, a serine protease abundantly
found at injury/ wound sites (McColl et al., 2003), therefore it is necessary to confirm
this result with our internal VHD-FLAG VEGFC and VEGFD constructs. Plasmin,
incubated with VEGFD-VHD-FLAG, revealed complete processing at 10 units (U)/mL
concentration (equivalent to 10 µmole of VEGFD per minute per mL) within 2 hours,
whereas the enzyme availability might not be sufficient to digest VEGFD at lower
concentration of plasmin (0.1 U/mL). This result indicated VEGFD proteolysis is dosedependent of plasmin (Fig. 38).
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Figure 38. Plasmin enhances VEGFD processing. VEGFD-VHD-FLAG was incubated with plasmin
at different concentrations (10 U/mL, 0.1 U/mL, and 0.001 U/mL respectively) for 2 hours and
samples were taken at regular intervals (30 min, 1 hour, and 2 hours). Complete proteolysis of
VEGFD was observed at 10 U/mL plasmin. NT, amino terminus; VHD, VEGF homology domain;
CT, carboxyl terminus.
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On the other hand, plasmin at different concentrations was incubated with VEGFC-VHDFLAG, revealed incomplete digestion of VEGFC, and indicated potential degradation of
substrate (at 10 U/mL of plasmin) within 2 hours (Fig. 39). The band representing VHD
structure (21 KDa) did not show up as product of VEGFC proteolysis in presence of
plasmin. ADAMTS3 was used as positive control for this assay. This result showed
plasmin does not activate VEGFC through proteolysis.
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Figure 39. Plasmin unspecifically digests VEGFC. VEGFC-VHD-FLAG was incubated with plasmin
at different concentrations (10 U/mL, 0.1 U/mL, and 0.001 U/mL respectively) for 2 hours and
samples were taken at regular intervals (30 min, 1 hour, and 2 hours). ADAMTS3 was used as
positive control. NT, amino terminus; VHD, VEGF homology domain; CT, carboxyl terminus.

These findings not only confirmed in vitro observations reported by other research
groups, but also indicated plasmin could be a regulator for VEGFD activity in vivo. The
latter idea was indeed followed up with in vivo studies in inflammation and wound
healing models, where the presence of plasmin is abundant.
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4.9

Chapter discussion

Prior to the start of this study, ADAMTS3 has only been known as a procollagen Npropeptidase, which facilitates collagen maturation (Fernandes et al., 2001; Colige et al.,
2005). Here, the biochemical assays demonstrated a novel finding by revealing
ADAMTS3 as a direct mediator of VEGFC N-terminal proteolysis. Both loss-of-function
and rescue experiments indicated ADAMTS3 is the sole protease that cleaves VEGFC Nterminus. Our finding, therefore, was consistent with that was suggested by Jeltsch et al.
(2014), but also extended further to generate an ADAMTS3-free in vitro environment.
HEK293T cells are able to express endogenous ADAMTS3 and CCBE1, which can
process overexpressed VEGFC if enough time is given. This problem normally leads to
false positive read-outs or lack of negative control in VEGFC proteolysis or phosphoVEGFR3 ELISA assays. The ADAMTS3-deficient HEK293T cell line enabled our study
to overcome those experimental limitations, as well as to conduct ADAMTS3 structural
study. For many years, ADAMTS3 has been solely considered as a procollagen activator,
and its enzymatic specificity was reported to be dependent on C-terminal domains
(Fernandes et al., 2001). Our series of truncated ADAMTS3 mutants showed that most of
the C-terminal domains are dispensable in the context of VEGFC proteolysis, and the Nterminal catalytic domain is responsible for cleaving VEGFC. Interestingly, as soon as
one or more of C-terminal domains is removed, truncated proteins became more
vulnerable to protein degradation, resulting in additional lower bands on the blot. This
observation suggested the C-terminus domains are important for ADAMTS3 structural
integrity.
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A key molecular finding in this study is that VEGFC, ADAMTS3, and CCBE1 form a
trimolecular complex that is required to proteolytically activate VEGFC, and that this
activation mechanism can take place in the extracellular environment in a manner that
does not require the LEC or the VEGFR3 receptor. Previous studies have revealed a role
for CCBE1 in VEGFC proteolysis (Le Guen et al., 2014; Roukens et al., 2015) and
suggested that ADAMTS3 cleaves VEGFC (Jeltsch et al., 2014), but a clear picture of
how these secreted proteins interact and how their interaction regulates lymphatic
vascular growth has not emerged. Here, our studies demonstrated that ADAMTS3
strongly associates with CCBE1, whereas both CCBE1 and ADAMTS3 individually have
low binding affinity towards VEGFC. Only when all three components are present, the
temperature sensitive VEGFC/ ADAMTS3/ CCBE1 complex is formed. Our model of
VEGFC processing was proposed to report our understanding on how VEGFC undergoes
N-terminal proteolysis (Fig. 40). Secreted protease ADAMTS3 does not bind readily to
VEGFC, thus the proteolysis is regulated via the formation of VEGFC processing
complex. When secreted CCBE1 interacts with ADAMTS3, it potentially causes a
conformational change in the structure of ADAMTS3, allowing the protease to associate
with VEGFC spatially and temporally. The complex remains stable until required
conditions are met, then ADAMTS3 executes its enzymatic activity to release NT from
VHD, which triggers VEGFC/ VEGFR3 signaling cascade. Since it was shown that
VEGFC processing complex could form in absence of LECs or VEGFR3 receptor, it is
possible that the localizing factor of this complex might lie in the N-terminal domains of
CCBE1 (i.e. CCBE1 175), which is not responsible for facilitating VEGFC proteolysis.
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This localization event could be mediated through binding of CCBE1 to extracellular
matrix (ECM) to bring the complex spatially to cell surfaces during lymphatic growth.
It has generally been thought that VEGFC and VEGFD are functionally redundant
VEGFR3 ligands since gain of function studies revealed that VEGFC and VEGFD have
equally powerful lymphangiogenic effects in vivo (Rissanen et al., 2003, Anisimov et al.,
2009), but genetic loss of function studies have only demonstrated a critical role for
VEGFC during lymphatic development but not VEGFD (Karkkainen et al., 2004; Koch
et al., 2009). Our Edman sequencing study and that of Marc Achen’s group concur in the
identification of the VEGFD site of N terminal cleavage following expression in HEK
cells ex vivo. Both labs identify primary cleavage immediately following the R88 in the RFAA sequence, which is consistent with VEGFD cleavage by a serine protease. The
finding that VEGFD proteolysis takes place independently of ADAMTS3 and CCBE1 in
vitro demonstrates a remarkable difference in the proteolysis regulation of the two
lymphangiogenic factors that suggests new insight into their distinct in vivo roles. Key
support for this division of lymphangiogenic labor is that ADAMTS3 is exclusively
required for VEGFC proteolysis but not VEGFD. In contrast, our studies confirmed
plasmin, a fibrinolytic serine protease that is activated at sites of tissue injury and
inflammation (Romer et al., 1996), as capable of cleaving VEGFD (McColl et al., 2007).
Further in vivo studies that more precisely define the distinct roles of VEGFC versus
VEGFD in established models of wound healing/ inflammatory lymphangiogenesis
would help test this partitioned model of VEGFC and VEGFD lymphangiogenic
function.

77

Figure 8

A

CCBE1

ADAMTS3

ADAMTS3
EGF-like Collagen-like

serine protease
proenzyme

EGF-like Collagen-like

NT
CT

S
S

S
S

VHD
VHD

CT
NT

NT

VEGFC

S
S

CT

VHD

CT

NT

active serine protease

ADAMTS3

S
S

CT

VEGFD

EGF-like Collagen-like
NT

S
S

VHD

S
S

VHD
VHD

CT
NT

NT
CT

S
S

VHD
VHD

S
S

CT

NT

ECM
VEGFR3

VHD
VHD

LEC

Lymphangiogenesis

B

Figure 40. Molecular mechanisms of VEGFC and VEGFD activation. VEGFC is activated by a
VEGFC-ADAMTS3-CCBE1
complex formation (left). CCBE1
binding to ADAMTS3 viahealing
the CCBE1
Development
Inflammation/wound
C terminus (left) is predicted to confer a conformational change that permits the enzyme to associate
with and cleave VEGFC (middle). N terminal cleavage of VEGFC releases the VHD that is able to
Fibrin
& serine
protease
activate VEGFR3 on theCCBE1
lymphatic endothelial cell (LEC). The
CCBE1
N terminus
may bind
extracellular matrix (ECM) to localize the complex spatially during lymphatic growth. In contrast,
VEGFD is activated independently of ADAMTS3 and CCBE1, most likelyVEGFD
through a serine protease
generated at sites of inflammation (right). The disulfide bond represents the fifth immunoglobulin-like
(Ig-like) domain of VEGFR3, which is proteolytically processed.

VEGFC
ADAMTS3
BEC

LEC

78

CHAPTER FIVE
Investigation of the VEGFC processing complex in vivo
5.1

Rationale

Our biochemical studies have demonstrated strong evidence for the existence of VEGFC
processing complex in vitro, in which CCBE1 and ADAMTS3 are required as
indispensable components of the complex. Our next goal was to examine whether this
hypothesis would hold its validity in vivo. Published studies have demonstrated that
CCBE1 can enhance the lymphatic endothelial cell (LEC) response to VEGFC in mice
(Jeltsch et al., 2014) and in fish (Le Guen et al., 2014), but direct assessment of the role
of CCBE1 in VEGFC-mediated LEC responses in vivo is not possible in the developing
mouse or fish because loss of CCBE1 results in a complete absence of lymphatic vessels
(Hogan et al., 2009; Bos et al., 2011). Using the conditional Ccbe1-deficient mouse
model developed in the lab (Zou et al., 2013), we were able to confirm the role of
CCBE1 in postnatal lymphatic growth mediated by VEGFC but not VEGFD.
Furthermore, the Adamts3-deficient mice (from KOMP) displayed lack of embryonic
lymphatics that also demonstrated the requirement of this specific metalloproteinase in
lymphangiogenesis in vivo, despite of being highly homologous to ADAMTS14 and
ADAMTS2. Therefore, our in vivo evidences, in line with the in vitro findings provided
strong insight and understanding into the mechanism in which VEGFC is processed by
ADAMTS3 and CCBE1.
This chapter was greatly contributed by the in vivo work from Dr. David Enis, a former
postdoctoral fellow in the Kahn lab.
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5.2

CCBE1 is dispensable for the maintenance of mature lymphatic vessels

To directly address the role of CCBE1 in postnatal lymphangiogenesis, we deleted
CCBE1 in conditional Ub-CreERT2;Ccbe1fl/- animals at timely manner. Neonatal
induction of Ccbe1 deficiency at birth showed lack of lymphatic (LYVE1+) vessels in the
ear and the skin, sites of postnatal lymphangiogenesis, by age 4 weeks (Fig. 41). CCBE1,
as during embryogenesis, is required for new lymphatic vessel growth after birth.
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Figure 41. CCBE1 is required for postnatal
to
adult lymphatic vessel growth. Tamoxifen was administered
adult
Controlfl/- (“neonatal CCBE1 KO”) and Ccbe1fl/Control
Ub-CreERT2;Ccbe1
littermate
(“control”)
animals
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CCBE1 KO
immediately after birth and analyzed at age 4 weeks. (A-D) The lymphatic network of the ear assessed
by anti-LYVE1 whole-mount staining. Images shown are representative of 4 separate experiments.
(E-H) Neonatal CCBE1 KO animals exhibit reduced lymphatic density in the skin. Imaging of dorsal
skin lymphatics in Prox1-GFP animals (E & F) and LYVE 1 immunostaining of skin sections (G &
H). Arrows point to cutaneous lymphatic vessels. Images shown are representative of 3 separate
experiments. Scale bars indicate 50 microns. The assay was done by Dr. David Enis.
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Figure 42. CCBE1 is dispensable for the maintenance of mature lymphatic vessels. Tamoxifen was
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VEGFR3. Arrows point to cutaneous lymphatic vessels. Images shown are representative of 4 separate
experiments. Scale bars indicate 50 microns. The assay was done by Dr. David
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5.3

CCBE1 is required for VEGFC to stimulate lymphatic endothelial cell

proliferation in vivo
To test whether CCBE1 specifically regulates VEGFC responses in vivo, we injected fulllength VEGFC (VEGFC-FL)-expressing adenoviral vectors into the skin of adult CCBE1
KO and littermate control animals, and harvested after 72 hours. The precise site of
VEGFC expression was marked by red fluorescence generated from a small amount of
co-injected adeno-mCherry (Fig. 43). This technique was extremely helpful for localizing
the injection site, as it could not be identified without m-Cherry fluorescence.

Ad-mCherry injected dorsal skin

Visible light

Fluorescence

Merge

Figure 43. Detection of cutaneous adenoviral expression using adeno-mCherry. Adeno-mCherry was
added to adeno-VEGFC-FL at the time of injection and the site of expression was identified using
fluorescent microscopy prior to tissue harvest for assessment of lymphatic proliferation and cell
number. Magnification of images shown is 10X. The assay was done by Dr. David Enis.
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LEC proliferation was measured by cell number, and mitotic index calculated by
immunostaining for BrdU that was injected 12 hours prior to sacrifice (Fig. 44). In
control animals, adenoviral expression of VEGFC-FL stimulated strong LEC
proliferation that was manifest by both the large fraction of LEC nuclei that were BrdU+
(approx. 35-40%) and by an increase in LEC cell number.

In contrast, adenoviral

VEGFC-FL failed to stimulate any increase in BrdU uptake or LEC number in adult
CCBE1 KO animals.
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Figure 44. VEGFC is not lymphangiogenic in adult Ccbe1-deficient animals. (A) Adenovirus
fl/AAV9-VEGFCN C
AAV9-VEGFC-FL
expressing full length
VEGFC (Ad-VEGFC-FL) was injected into
the skin of Ub-CreERT2;Ccbe1
animals in which Ccbe1 had been deleted by tamoxifen administration. Lymphatic vessels were
analyzed 72 hours after adenovirus injection. Arrows indicate BrdU+ LEC nuclei. (B) The percentage
of LEC nuclei that were BrdU+ (“mitotic index”) in the skin of adult CCBE1 KO and control animals
following exposure to adenovirus expressing full length VEGFC is shown. N=5 in each group; **
indicates P<0.001. (C) LEC proliferation in the skin of adult CCBE1 KO and control animals
following exposure to adenovirus expressing full length VEGFC was calculated by counting LEC
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To further test the role of CCBE1 in VEGFC-mediated responses in vivo, we attempted to
rescue VEGFC-FL responses in adult CCBE1 KO mice by expression of CCBE1-V5.
Injection of adeno-associated virus expressing CCBE1-V5 into the skin of adult CCBE1
KO animals 4 weeks prior to the administration of VEGFC adenovirus successfully
restored VEGFC-FL-induced LEC proliferation in adult CCBE1 KO animals (Fig. 45),
confirming that loss of VEGFC responses is due specifically to the lack of CCBE1 and
that CCBE1-V5 is biologically active in vivo. These studies demonstrate that CCBE1 is
required for lymphatic endothelial responses to VEGFC in vivo, even when an intact
lymphatic network is presented with very high levels of VEGFC ligand.
Supplemental Figure 3
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Figure 45. CCBE1-V5 rescues lymphangiogenesis in adult CCBE1 KO animals. Pre-treatment of
adult CCBE1 KO skin with adeno-associated virus expressing CCBE1-V5 (AAV9-CCBE1-V5)
restores the proliferative response of LECs to Ad-VEGFC-FL in adult CCBE1 KO animals. The
BrdU+ cells in the adult CCBE1 KO skin that is exposed to only Ad-VEGFC-FL (lower right panel)
are in the hair follicle. The data shown are representative of 5 separate experiments. Scale bars
indicate 50 microns. The assay was done by Dr. David Enis.
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5.4

Figure 1

The fully processed VEGFCΔNΔC bypasses CCBE1 requirement in vivo
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Figure 46. CCBE1 is required for VEGFC-mediated lymphangiogenesis in tibialis muscle. Adenoassociated virus (AAV9) expressing full length VEGFC (VEGFC-FL) was injected into the tibialis
muscle of adult CCBE1 KO or control animals. Lymphatic growth was detected using LYVE1 and
PROX1 immunostaining. Scale bars indicate 50 microns. The assay was done by Dr. David Enis.
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Figure 47. The fully processed ligand VEGFC
bypasses the requirement of CCBE1 in vivo.
Adeno-associated virus (AAV9) expressing the core domain of VEGFC released by proteolysis of the
ΔNΔC
N and C termini (VEGFC
) was injected into the tibialis muscle of adult CCBE1 KO or control
animals. Lymphatic growth was detected using LYVE1 and PROX1 immunostaining. Note that
ΔNΔC
lymphatic growth stimulated by VEGFC
tightly encircles muscle fibers and lacks the typical
branched vascular appearance. Scale bars indicate 50 microns. The assay was done by Dr. David Enis.
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5.5

VEGFD-mediated lymphangiogenesis is independent of ADAMTS3/ CCBE1

in vivo
Since VEGFD proteolysis is independent of ADAMTS3/ CCBE1 in vitro, we next
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expressed full length VEGFD in wild type and adult CCBE1 KO mouse muscle using
ADAMTS3 KO

293T
Bto test whether VEGFC and
adeno-associated virus
VEGFD are activated through distinct
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mechanisms in vivo. In contrast to VEGFC, AAV9-VEGFD drove lymphatic vessel

35

growth in both wild type and35adult CCBE1 KO animals (Fig. 48). This means loss of
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Figure 48. VEGFD is lymphangiogenic in Ccbe1-deficient animals. Adeno-associated virus (AAV)
expressing full length VEGFD (VEGFD-FL, left) was injected into the tibialis muscle of adult CCBE1
KO or control animals. Lymphatic growth was detected using LYVE1 immunostaining and compared
with mock-injected animals. The data shown are representative of 3 separate experiments. Scale bars
indicate 50 microns. The assay was done by Dr. David Enis.

87

5.6

ADAMTS3 is required for lymphatic development in vivo

Our in vitro studies revealed that ADAMTS3 plays a central and even necessary role in
the proteolytic activation of VEGFC in HEK293T cell conditioned medium ex vivo.
However, ADAMTS3 is highly homologous to ADAMTS14 and ADAMTS2, proteases
that can also cleave procollagen and are also expressed in the developing mouse embryo
(Bolz et al., 2001; Le Goff et al., 2006). Thus, the ex vivo requirement for ADAMTS3
may merely reflect a lack of expression of related proteases by HEK293T cells and not
accurately predict its in vivo lymphangiogenic role. To define the role of ADAMTS3 in
vivo, we next studied lymphatic development in Adamts3-deficient mouse embryos that
was generated by KOMP. A null Adamts3 allele (Adamts3-) was induced by deletion of
exon 3 in the Adamts3 gene, an event that removes the propeptidase domain and inserts
multiple STOP codons immediately downstream of exon 2, resulting in an Adamts3
mRNA predicted to encode a truncated protein lacking the catalytic domain (Fig. 49).

2

2

3

3

4

4

Figure 49. Generation of Adamts3-/- mice using gene-trapped targeting. Gene targeting strategy for
replacement of Adamts3 exon 3, flanked by 2 loxP sites, with an IRES-LacZ expression cassette is
shown. All components were labeled accordingly. Figure was adapted from Sanger Institute technical
data sheet.
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Once the Adamts3- allele got into germ line, it provided heterozygous Adamts3+/- animals
that were then intercrossed to generate Adamts3-/- embryos and littermate controls. In
E14.5 mouse embryos, the loss of ADAMTS3 resulted in severe cutaneous edema (Fig.
50), a phenotype consistent with a defect in embryonic lymphatic vascular function.
Besides, another phenotype of E14.5 Adamts3-/- embryos is anemia and fetal liver defect,
which is phenocopy of Ccbe1-/- embryo (Zou et al., 2013). Investigation of the anemic
defect, however, is out of scope of this thesis.

Control

Adamts3-/-

Figure 50. Loss of ADAMTS3 results in severe cutaneous edema at E14.5. Arrow indicates
translucent space between the skin and body indicative of edema.

Histologic examination revealed normal LYVE1+; PROX1+ lymphatic vessel growth in
the skin and deeper tissues of Adamts3+/- and Adamts3+/+ control littermates, but
LYVE1+; PROX1+ lymphatic vessels were entirely absent in embryos lacking
ADAMTS3 (Fig. 51), consistent with a recent report of independently derived Adamts3-/89

animals (Janssen et al., 2016). In the skin, macrophages (LYVE1+; PROX1-) fill up the
space where lymphatic vessels normally locate while the jugular lymph sacs are
completely missing in Adamts3-deficient embryos.
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Figure 51. ADAMTS3 is required for lymphatic development in mouse embryos. Loss of ADAMTS3
results in a complete lack of PROX1+; LYVE1+ lymphatic endothelial cells in the E14.5 embryo. Note
the presence of smaller lymphatic vessels in the skin (A) and larger lymphatic vessels adjacent to the
dorsal aorta and cardinal vein (B) in the wild-type littermate control embryo. Scale bars indicate 50
microns.
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To assure that ADAMTS3 is lymphatic-specific, we examined the cardiovasculature and
blood vessel establishments in the E14.5 Adamts3-/- embryos.

PECAM and FLK1

staining for endothelial cells revealed normal blood vessel patterning and growth in
Adamts3-/- embryos (Fig. 52), a finding consistent with the observation that Adamts3-/embryos were not growth retarded. These findings closely phenocopy those previously
reported for both Vegfc-/- (Karkkainen et al., 2014) and Ccbe1-/- (Bos et al., 2011; Zou et
al., 2013) embryos, and reveal that ADAMTS3 plays an indispensable and non-redundant
role for lymphatic vascular development in mice.
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Figure 52. ADAMTS3 is not required for blood vessel development. Blood vessels from an
ADAMTS3-deficient and control embryo were identified using anti-PECAM and anti-FLK1
immunostaining. Scale bars indicate 50 microns.
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5.7

Analysis of the role of VEGFC versus VEGFD in a peritoneal inflammatory

lymphangiogenesis model
Since our studies revealed potential distinct mechanisms of regulating lymphangiogenesis
between VEGFC versus VEGFD, we proposed to test the role of VEGFC vs. VEGFD in
a peritoneal inflammatory lymphangiogenesis model using adult knockout animals. The
lipopolysaccharide (LPS)-induced model, previously used by the Koh lab and others to
measure lymphangiogenic responses in the setting of inflammation (Kim et al., 2009),
was implemented because lymphatic growth takes place on the peritoneal surface of the
diaphragm where it can be visualized in its entirety by whole mount staining for
lymphatic vessels (using anti-LYVE1 antibodies) and quantitated by calculating
lymphatic vessel area as a % of total area. This investigation was greatly contributed by
the Alitalo research group (University of Helsinki). The animals used in this assay were
control animals, adult constitutive Vefgd-deficient animals, and adult animals, in which a
conditional allele of VEGFC was deleted ubiquitously after tamoxifen administration
(Vegfcfl/fl; Rosa26-CreERT2).
Using this peritoneal inflammatory model, we were able to observe a possible trend
toward reduced inflammatory lymphangiogenesis with loss of VEGFD but not with loss
of VEGFC (Fig. 53). Unfortunately, the assay demonstrated a high degree of variability
that ultimately precluded us from drawing any significant conclusions regarding the roles
of VEGFC and/or VEGFD in inflammatory lymphangiogenesis. In summary, this assay
did not provide solid evidence to demonstrate the potentially different role of VEGFC vs.
VEGFD in peritoneal inflammatory lymphangiogenesis.
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challenging than we initially thought and will require a separate series of studies
that employ a number of approaches with quantitative measures of both
lymphatic vessel growth and function. We remain committed to doing such
studies, but it is now clear that they will extend beyond the scope of the present
manuscript. We therefore thank Reviewer B for suggesting/encouraging this line
of investigation, and we hope that future studies will successfully address it.
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5.8

Analysis of de novo lymphangiogenesis in a skin wound healing model

Both VEGFC and VEGFD were reported to enhance lymphatic growth in adult animals
(Anisimov et al., 2009), however, how these two ligands regulate regeneration of
lymphatic vessels at injury sites, and what the growth pattern of the these new lymphatics
is are not yet known. Therefore, an in vivo wound healing model – the full thickness
excision – was implemented to address this specific question. An injury (1.5cm x 1.5cm)
was introduced onto dorsal skin of experimental animals (day 0), and the healing process
is observed within 18 days (Fig. 54). A distinctive feature of the newly healed skin is
hairless where the new epidermis has closed the wound, however skin morphology has
not completely restored. This observation was consistent with other previous studies on
mouse skin wound healing (Shaw and Martin, 2009; Koch et al., 2009).

Day 0

Day 18

Figure 54. Mouse adult dorsal skin was healed within 18 days after full thickness excision. The newly
healed skin is hairless, which is distinctive to undamaged skin.
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The H&E staining provided a brief insight into how the new vasculature growth within
the wound site (Fig. 55). Undamaged skin has a very thin layer of epidermis while its
dermis layer expands to most of the skin cross-section. By day 7 after skin excision, the
inflammatory site was resolved and dried out. No clear sign of the new epidermis layer
formation before wound contraction around day 10 (data not shown). The skin was
healed from day 14 onwards when new epidermis and dermis layers are separated.
However, the vasculature morphology, especially the new dermis layer was not restored
to its original condition. The healing process continued to proceed as shown on day 18.
The new skin on day 18 did not have any hair follicle formation, which explained why it
was hairless. This observation suggested the mouse skin healing could be achieved in the
first two weeks, then followed up by structural remodeling until the resolution phase is
complete.

Day 0

Day 7

Day 14

Day 18

Figure 55. Mouse skin wound healing process by H&E staining. On day 0, undamaged skin of adult
animals was used as control for healing end-point, which had not been achieved by day 18. The new
epidermis and dermis layers were separated between day 7 and day 14. The new skin has no hair
follicle formation.
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Mouse skins were harvested at different time points and cross-sections were examined by
histology staining with LYVE1+ and PROX1+ antibodies for lymphatic distribution in the
skin. In undamaged skin, LYVE1+; PROX1+ lymphatic vessels mostly localize in the
dermis and subcutaneous layers (Fig. 56). The epidermis-specific staining of K14
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Figure 56. Lymphatic distribution in the adult mouse skin. (A) Lymphatic vessels were detected
using LYVE1 and PROX1 immunostaining at 10x magnification. (B) Detection of the epidermis layer
(K14+) in undamaged skin. (C, D) Analysis of lymphatic vessels (LYVE1+; PROX1+) at higher
magnification (40x). Arrows indicate lymphatic vessels.

96

No lymphatic vessel was detected in the injury sites on day 4 after the surgery was
performed (Fig. 57). This observation confirmed that the skin healing is a de novo
lymphatic regeneration process from complete absence of lymphatic vessels in this
model.
In addition,
no detection ofregeneration
a new epidermis layer
(K14+)after
was detected
at this
Lack
of lymphatic
4 days
surgery
time point.

Day 4
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LYVE1
PROX1

LYVE1
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Figure 57. No lymphatic vessel (LYVE1+; PROX1+) was detected on day 4 after surgery; at (A) 10x
magnification, and (B) 40x magnification.
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Lymphatic (LYVE1+; PROX1+) vessels started to show up on day 7, mostly in the
subcutaneous area where new skin attached to the dorsal spinal muscles. These
lymphatics were large vessels with high number of PROX1+ nuclei (Fig. 58). In contrast,
no LYVE1+; PROX1+ vessels was detected in the new dermis layer at this point. This
observation suggested that new lymphatics potentially grow upwards from subcutaneous
tissues, rather than by reconnecting existing lymphatic vasculature around injury site.
Besides, no K14+ staining was detected, implying an incomplete formation of a new

Lymphatics regenerate in the subcutaneous layer on day 7
epidermis layer.
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Figure 58. New lymphatic regeneration on day 7 after the full thickness excision. (A) Lymphatic
(LYVE1+; PROX1+) vessels were mostly detected in the subcutaneous areas (4x magnification). (B)
No detection of the new epidermis layer (K14+) in day 7 skin. (C) No lymphatic vessel was detected in
the new dermis layer; (D) Robust growth of subcutaneous LYVE1+; PROX1+ vessels (40x
magnification). Arrows indicate lymphatic vessels.
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By day 14, new lymphatics (LYVE1+; PROX1+) were detected in both new dermis and
subcutaneous layers (Fig. 59). The lymphatic vessels on day 14 were relatively smaller in
size compared to those detected on day 7. In combination with what was observed on
day 7, in vivo observations suggested that lymphatic vessels could migrate from the
subcutaneous area into the new dermis layer from day 7 to day 14 after the surgery.
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Figure 59. New lymphatic regeneration on day 14 after the full thickness excision. (A) Lymphatic
(LYVE1+; PROX1+) vessels were detected in the dermis and subcutaneous areas (4x magnification).
(B) The complete epidermis layer (K14+) was formed by day 14 after the surgery. (C, D) New
lymphatic vessels were in the dermis and subcutaneous at 40x magnification, respectively. Arrows
indicate lymphatic vessels.
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On day 18, the overall structure of the newly healed skin was similar to that was observed
on day 14 (Fig. 60). Although dermis lymphatics started to separate themselves towards
upper areas of the dermis layer, morphology of the new skin was still significantly
different to undamaged skin. This suggested further remodeling must be required to
achieve complete restoration. However, lymphatic regeneration looked complete at this
time point. In order to confirm this observation, the number of new lymphatic vessels
were quantified andconcentrate
compared between
time points.
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the new
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Figure 60. Further lymphatic regeneration on day 18 after the full thickness excision. (A) Lymphatic
(LYVE1+; PROX1+) vessels were detected in the dermis and subcutaneous areas (10x magnification).
(B) The complete epidermis layer (K14+) of the new skin. (C, D) New lymphatic vessels were in the
dermis and subcutaneous at 40x magnification. Arrows indicate lymphatic vessels.
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To illustrate the process of lymphatic growth during wound healing, the number of
lymphatic (LYVE1+; PROX1+) vessels were counted in 40 different high power fields
(40X Objective and 10X Ocular ~ 2.37mm2) for each experimental animal at different
time points, i.e. day 4, day 7, day 14, and day 18. The quantitative result was consistent
with our visual observations, and confirmed near completion of lymphatic regeneration
by day 18 after the surgery (Fig. 61). Thus, this model of de novo lymphatic generation

hatic vessels regenerate during wound healing

has been validated by both qualitative and quantitative approaches for future study of
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Figure 61. Quantification analysis of lymphatic regeneration in dorsal skin wound healing. Skins were
fixed, sectioned, and stained for LYVE1 PROX1 antibodies. The number of LYVE1+; PROX1+
vessels per high power field were manually counted with a Nikon Eclipse 80i microscope. Bars
represent the mean ± SEM. Statistical analysis using ordinary one-way ANOVA. The number N for
each group provided underneath. *** indicates P<0.001.
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5.9

Chapter discussion

CCBE1 has clearly demonstrated, according to our in vitro experiments, as a required
cofactor to facilitate VEGFC processing complex assembly. Here, our in vivo conditional
Ccbe1-deficient mouse model provided a unique opportunity to study the role of CCBE1
during adulthood, when the lymphatic vasculature has completely established. The
tamoxifen inducible system was extremely helpful for inducing CCBE1 deletion at timely
manner. To our surprise, CCBE1 is required for new lymphatic growth after birth, but not
for the maintenance of mature lymphatic vasculature. In addition, the in vivo observation
that loss of VEGFC responsiveness in Ccbe1-deficient animals can be rescued by the
fully processed active ligand VEGFCΔNΔC supports our in vitro findings and a mechanism
in which CCBE1 participated in VEGFC proteolysis in vivo. The lymphatic structures
generated in response to VEGFCΔNΔC expression in the muscle of mature mice appeared
highly abnormal as they tightly encircled the muscle fibers that expressed VEGFCΔNΔC
and did not form typical branching structures. In contrast, full length VEGFC stimulated
the growth of branched lymphatic structures, presumably due to the influence of
endogenous regulators such as CCBE1 and ADAMTS3. Thus, this implies the regulation
of VEGFC proteolysis in vivo can be highly temporal and spatial, which may be
disrupted by simple over-expression of either CCBE1 or ADAMTS3 in vitro.
Why has CCBE1 evolved to play such an important role in the growth of lymphatic but
not blood vessels? During development, once the programmed vasculogenesis is
completed, blood vessels expand organically with growing organs in order to feed the
rising cell population (Potente et al., 2011). On the other hand, lymphatic vessels grow
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pattern with VEGFC to create a trail of active ligands to promote LECs migration. In
other words, the primary role of ADAMTS3-CCBE1 is to lay down a roadmap for LECs
to follow and rapidly create the primary
lymphatic network (Fig. 62). Such a precise
Lymphangiogenesis
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spatiotemporal blueprint may be required for the lymphatic vasculature to expand as
rapidly as it does in mid-gestation, e.g. from a limited number of progenitor cells to a
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functional network in only a few days in the mouse embryos.
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Figure 62. Proposed lymphangiogenic roles VEGFC in vivo. VEGFC activation by ADAMTS3 and
CCBE1 provide a mechanism for spatial patterning of the developing lymphatic vasculature. The midgestation cardinal vein with newly specified LECs that are in the process of sprouting to form the
lymphatic network is shown. The area encircled by the dotted line represents a zone of active VEGFC.
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It is surprising that, despite its redundant function with ADAMTS2 for procollagen
processing (Colige et al., 2005) and close homology to ADAMTS14 (Bolz et al., 2001),
ADAMTS3 plays a non-redundant role in lymphatic development in mice. Adamts3-/animals phenocopy the phenotypes of Vegfc-/- and Ccbe1-/- mice that provided solid
evidence for existence of VEGFC processing complex in vivo, as previously
demonstrated in our biochemical assays. The strong physical association observed
between ADAMTS3 and CCBE1 in our studies suggests that the functions of these two
proteins are tightly linked. Mutations in CCBE1 account for only 25% of Hennekam
syndrome cases (Alders et al., 2009; Alders et al., 2013). The highly specific disruption
of lymphatic development with loss of ADAMTS3 in developing mice suggests that loss
of function mutations in ADAMTS3 may also contribute to Hennekam syndrome. Future
studies addressing the biochemical and genetic relationships between of these proteins
will better define how this complex regulates lymphangiogenesis in vivo as well as its
contribution to human lymphatic diseases.
The peritoneal lymphangiogenesis model was used to examine the requirement of
VEGFC and VEGFD in inflammatory lymphangiogenesis in adult animals that were
engineered to genetically lack VEGFC, VEGFD, and both VEGFC and VEGFD.
Although an excessive degree of variability was observed in our results, we do not
believe that the failure of these studies reflects problems with the animals used. Firstly,
all animals were 2-3 months in age at the time of use and were on a pure C57Bl/6
background. Second, variability was as high in animals that did not receive tamoxifen
treatment (e.g. control or VEGFD constitutive KOs) to induce gene deletion as in those
that did (e.g. VEGFC conditional KO). Third, the assay was performed independently
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from two different laboratories. It is possible that, unlike developmental studies in which
a highly controlled and stereotypic process can be reproducibly interrogated, adult
inflammatory lymphangiogenic assay has not yet been standardized to the point where
these genetic studies are straightforward and interpretable. There are likely many
variables that need to be addressed, including the type of inflammation (and therefore the
type of protease activation), the methods available to measure lymphangiogenic growth
and lymphatic function, and the organ in which the assay is performed. Thus testing the
roles of VEGFC and VEGFD in inflammatory lymphangiogenesis is challenging and
requires an established model with quantitative measures of both lymphatic vessel growth
and function.
In search for a quantitative approach to examine the roles of VEGFC and VEGFD in
adult lymphangiogenesis, we pursued a model in which lymphatic growth is a local
process that is served by serine proteases like plasmin, which activates VEGFD by
cleavage at a distinct N terminal sequence. The full thickness excision, which completely
removed an area of dorsal skin at the site of injury, is a potential candidate model as the
wound healing process provides high abundance of plasmin and other serine proteases. In
the same context, our adeno-virus injection assays showed that CCBE1/ADAMTS3 are
active to process VEGFC and VEGFC can promote lymphangiogenesis in the skin. The
dorsal skin wound healing, where both VEGFC and VEGFD are active, is the model to
study roles of these lymphangiogenic ligands during adulthood. To our interest, new
lymphatics did not reconnect from the existing lymphatic vasculature surrounding the
injury site. Instead, new lymphatic vessels budded out from subcutaneous tissues, and
then migrated upwards to the new dermis layer (Fig. 63). Importantly, we were able to
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quantify the number of new lymphatic (LYVE1+; PROX1+) vessels at specific time
points during wound healing process. Thus, this assay provided a novel tool to study de
novo lymphangiogenesis in adult animals, rather than a conventional lymphatic
regeneration model. We believe the full thickness excision assay could answer the
question whether or not the roles of VEGFC and VEGFD are distinct in adult
lymphangiogenesis. Indeed, our next step would be to apply this procedure to VEGFC
conditional KO, VEGFD KO, and VEGFC/VEGFD double KO animals to identify the
roles of each lymphangiogenic factor in new lymphatic development in adulthood. If
VEGFD, but not VEGFC, is responsible for adult de novo lymphangiogenesis, the wound
healing process in VEGFD KO and VEGFC/ VEGFD double KO animals are expected to
be similar, whereas VEGFC condition KO animal should not display any abnormalities
compared to control animals. A similar rationale could be applied if VEGFC, but not
VEGFD, drives lymphangiogenesis in adult skin healing. However, if VEGFC and
VEGFD work redundantly in adulthood, the double KO animals are expected to show
complete loss of lymphatic growth, whereas VEGFC conditional KO or VEGFD KO
only display partial loss of lymphangiogenesis compared to control animals. The
conclusion drawn from this study might provide a novel insight into the functions of
VEGFD, which has not yet been fully understood, and the relationship between the two
lymphangiogenic factors.
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Figure 63. Model of de
novo
Day
14 lymphangiogenesis in adult mouse skin. The full thickness excision
procedure removed epidermis and dermis layers from skin on day 0. A fibrin mess (including fibrins
and other ECM proteins) was formed to fill up the injury site. On day 7, new lymphatic vessels were
detected in the subcutaneous region and migrated upwards to the new dermis layer until day 14, when
the new epidermis layer was completely formed.
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CHAPTER SIX
Discussion and Conclusion
During embryonic development, lymphatic vessels arise after organs have formed and
rapidly create a vascular network through a highly stereotyped, spatially controlled
angiogenic program (Yang and Oliver, 2014). VEGFC is a critical regulator of this
process (Karkkainen et al., 2004; Ober et al., 2004), but the VEGFC homologue VEGFD
appears to play no required role in lymphatic development (Koch et al., 2009). VEGFC
and VEGFD contain N and C terminal extensions that are not found in VEGFA. Cell
culture studies performed almost 20 years ago first revealed that these extensions are
proteolytically removed (Joukov et al., 1997; Stacker et al., 1999), but the biological
significance of these observations has only recently begun to emerge from studies
connecting defects in lymphatic development associated with loss of the secreted protein
CCBE1 and a role for CCBE1 in VEGFC proteolysis (Jeltsch et al., 2014; Le Guen et al.,
2014; Roukens et al., 2015). However, a clear molecular understanding of these events
has not yet emerged due to difficulties in following VEGFC proteolysis, assessing its role
in lymphatic endothelial cell responses ex vivo and in vivo, and a lack of evidence
supporting a role for ADAMTS3 in lymphatic development. Our studies have addressed
these issues using molecular tags to follow VEGFC and VEGFD processing without
disturbing their molecular activity, genome editing to test the role of ADAMTS3 ex vivo,
and mouse genetic studies to test the roles of ADAMTS3 and CCBE1 in vivo. We find
that assembly of a VEGFC-ADAMTS3-CCBE1 complex regulates VEGFC activity, and
that loss of ADAMTS3 blocks lymphatic development in mice in a manner identical to
loss of CCBE1 or VEGFC. In contrast, proteolysis of the closely related VEGFD, a
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growth factor that is dispensable during lymphatic development, is independent of
ADAMTS3 and CCBE1 ex vivo and its lymphangiogenic activity independent of CCBE1
in vivo. These findings suggest that regulation of VEGFC activity by ADAMTS3 and
CCBE1 is a molecular mechanism for programmed lymphatic growth during
development, while the role of VEGFD may be connected to lymphangiogenesis that
takes place after lymphatic development is complete and regulated by a distinct
proteolytic activation mechanism.
One of our challenges in pursuing this study further is to understand how the spatial
relationship of VEGFC, ADAMTS3 and CCBE1 is important for productive
lymphangiogenesis. This question is raised after the fact that VEGFC ligands under in
vitro condition takes 18 hours to complete its NT cleavage, which is significantly longer
than rapid LEC sprouting that has been observed in vivo. The rationale to explain this
long incubation time is due to the HEK293T conditioned media environment where
secreted proteins are free to move and interact by chance. As freely as they move, it
might take longer time for all components of the VEGFC-ADAMTS3-CCBE1 complex
to assemble to perform proteolysis. In contrast, tight regulation of in vivo VEGFC
processing by	
   spatial intersection of ADAMTS3 and CCBE1 proteins in the extracellular
environment provides a previse roadmap for rapid ligand activation, which leads to LEC
sprouting and lymphatic growth. This notion is supported by our in vivo data showing
that full length VEGFC expression promotes normal growth of lymphatic structures in
the muscle of mature mice, presumably due to regulation of endogenous CCBE1 and
ADAMTS3. However, the processed ligand VEGFCΔNΔC that bypasses the regulation of
CCBE1/ ADAMTS3 generates highly abnormal lymphatic structures and impairs the
109

typical lymphatic branches. To understand the spatial relationship between these secreted
proteins, it is necessary to use mouse genetics with organ-specific Cre recombinases to
knockout each protein in potential organs and areas of interest. Observation of lethality or
significant phenotypes should indicate whether VEGFC or ADAMTS3 or CCBE1 is
expressed in a specific organ/ tissue, illustrating its source of expression. The selection
criteria of Cre recombinases is to target organs/ tissues, which surround areas of the
cardinal vein – the origin of LEC progenitors, and of the lymph sacs - the first lymphatic
vessels. Examples of potential Cre recombinases used in this study are Wt1-Cre
(mesothelium), SM22a-Cre (smooth muscle cells), Fsp1-Cre (fibroblasts), and Vav-Cre
(hematopoietic and endothelial cells). The location where each of these proteins is
expressed could provide an idea of how they spatially come to contact with one another.
A further step in studying the VEGFC-ADAMTS3-CCBE1 complex in vivo is to
engineer mouse genome with fluorophore-tag like mCherry or GFP or Cyan Fluorescent
Protein (CFP) to each component of the VEGFC processing complex. In the past,
transgenic VEGFA-GFP mouse was generated by Kishimoto et al., which suggested the
possibility of following VEGFC in vivo (Kishimoto et al., 2000). The gene editing
technology of CRISPR/ Cas9 in mice potentially allows transformation of in vitro genetic
modifications into transgenic mice in a more robust and convenient way than the
conventional method (Oji et al., 2016). Mice carrying fluorophore-tagged of VEGFC,
CCBE1, and ADAMTS3 could be analyzed by frozen section IHC to provide insight into
the complex assembly and spatial relationship between these secreted lymphangiogenic
factors in vivo. Our new understanding of VEGFC proteolysis mechanism and available
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technologies for transgenic mice generation could make it feasible to observe and analyze
the VEGFC processing complex in vivo in the near future.
There remains a molecular question of precisely how proteolysis activates the VEGFC
ligand to drive lymphatic development and growth. Our findings and previous studies
clearly demonstrate a requirement for proteolytic removal of N and C termini that are
covalently linked to each other for VEGFC to activate the VEGFR3 receptor. Several
molecular mechanisms may explain this requirement. The most straightforward
mechanism is that the presence of the N and C termini sterically prevents the VEGFC
core ligand (i.e. the VHD) from engaging the VEGFR3 receptor to induce receptor
signaling. Alternatively, the N or C terminus may actively oppose VEGFC activity, e.g.
by binding a distinct site in VEGFR3 or VEGFC itself. In the course of our studies, we
generated a VEGFC ligand that had an uncleavable 192 amino acid C terminus, one in
which the C-terminus was replaced with a 22 amino acid FLAG-V5 tag, and one in which
there was no C terminus following the VHD. All of these ligands were efficiently cleaved
at the N terminus, but we observed a progressive loss of VEGFR3 activation as the C
terminal extension grew in length from 0 to 22 to 192 amino acids. The progressive loss
of function conferred by longer C terminal tags supports the more straightforward model
of steric hindrance during VEGFC docking to VEGFR3 (Leppanen et al., 2013). This
also explains if N terminus is not completely removed from VHD, C terminus linked to N
terminus by a disulfide bond could block receptor binding of VHD. Thus, the importance
of proteolytic processing for VEGFC is that the ligand cannot activate VEGFR3 until it is
fully activated at a precise location of available CCBE1 and ADAMTS3. This tight
regulation of VEGFC activation is beneficial for lymphangiogenesis in vivo to prevent
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non-specific lymphatic sprouting and to preserve the role of VEGFC to be lymphaticspecific. Mutagenesis of cysteine residues, which form disulfide bonds, is a potential
direction to further understand how C terminus prevents VEGFC binding to VEGFR3.
Since N and C termini are linked to each other by a disulfide bond, mutation of cysteine
amino acids could disrupt this connection, which separates these fragments during the
formation of prepro-VEGFC and completely remove C termini from pro-VEGFC.
Although there are 8 cysteine residues available on the C terminus, the N terminus of
VEGFC contains only one cysteine residue, i.e. C83. Conversions of C83 (a polar residue)
into alanine (A) or phenylalanine (F) (non-polar residues), or into lysine (K) or glutamic
acid (E) (charged residues) are potential options for mutagenesis. Analysis of C83 mutants
by VEGFC cleavage assay and phosphor-VEGFR3 ELISA assay could indicate how
deletion of the disulfide bond contribute to activation of VEGFC, thus suggests the
importance of C terminus in regulation of VEGFC activity.
We propose a biological model in which VEGFC signaling is controlled by ADAMTS3
while VEGFD signaling is controlled by serine proteases, corresponding to roles in
developmental and inflammatory/ wound lymphangiogenesis, respectively. Although we
have gained a novel understanding of VEGFC processing, not much has been known
about regulation of VEGFD proteolysis. That serine proteases like plasmin and thrombin
have been shown to enhance VEGFD proteolysis suggests a question whether VEGFD
activation is strictly regulated or VEGFD is a common substrate of several serine
proteases. To have a better understanding to this question, VEGFD-V5 construct can be
generated, expressed in HEK293T, and used for co-immunoprecipitation with any
proteins bind to VEGFD at 4oC and/ or in addition of serine protease inhibitors. The
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presence of inhibitors and low temperature would inhibit any enzymatic activity and
maintain the complex of VEGFD and its binding proteins. The VEGFD-binding proteins
are then isolated and analyzed by mass spectrometry to identify all potential serine
proteases that bind and cleave VEGFD N terminus. The results would reveal how tightly
VEGFD proteolysis is regulated and lead to a better knowledge of why evolution brings
forth VEGFD, which undergoes similar proteolytic activation like VEGFC but does not
play a significant role in lymphangiogenesis.
Lymphedema is a common clinical condition in our society, there are approximately 10
million people suffering from lymphedema (mostly secondary lymphedema) in the
United States. The most common cause of secondary lymphedema is due to damage to
lymph nodes in surgeries and cancer treatment. Such damage interrupts the flow of lymph
on its way back to the circulation through the subclavian vein that results in tissue
swelling. Currently, there is no cure for this condition and no mouse model for secondary
lymphedema. To search for a potential therapeutic approach to mitigate this clinical
condition, a reliable mouse model for secondary lymphedema is required. The axillary
lymph node dissection (ALND) procedure should be tested on adult VEGFC or CCBE1
conditional KO mice to generate a mouse model for secondary lymphedema. Mendez et
al. applied the ALND model on wild-type mice and reported that the endogenous
regrowth of collateral lymphatic channels restores	
  interstitial fluid drainage, which results
in an ineffective lymphedema model (Mendez et al., 2012). However, all lymphatic
factors are active in wild-type mouse, it is expected that endogenous lymphatic
regeneration could remedy impaired lymph flow caused by removal of axillary lymph
nodes. In CCBE1 and VEGFC conditional KO adult animals under ALND treatment, the
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lack of endogenous lymphatic growth factor would significantly reduce or even inhibit
new lymphatic growth that maintain blockages to lymph flow, lead to tissue swelling and
lymphedema. This investigation could confirm the role of VEGFC in new lymphatic
growth in adult animals in addition to the study of wound healing. The lymphedema
mouse model might become a novel tool used to identify potential treatment for
lymphedema. A previous study reported that administration of adenovirally delivered
VEGFC enhanced growth of lymphatic capillaries and formation of collecting lymphatic
vessels in mice after lymph node removal (Tammela et al., 2007). According to Tammela
et al., newly generated lymphatic vessels can mature and become functional even without
the presence of lymph nodes. However, it has not been known if VEGFC can restore
lymph flow in mice with lymphedema due to the lack of a reliable animal model. The
outcome of this study promises a novel insight into clinical treatment for lymphedema.
Moreover, our understanding of VEGFC activity regulation demonstrates that CCBE1
and ADAMTS3 are as important lymphatic factors as VEGFC. This notion broadens
potential therapeutic options for lymphedema treatment. The use of CCBE1 and
ADAMTS3, which are regulatory proteins, could help avoid non-specific lymphatic
growth that might be caused by direct administration of VEGFC. Also, patients with
deficiency in CCBE1 or ADAMTS3 due to genetic mutations display similar symptoms
as those who have VEGFC mutations, but are not helped by VEGFC treatment. The roles
of CCBE1 and ADAMTS3 in lymphatic regeneration have not yet been fully
characterized and understood, therefore, it is reasonable to examine effects of CCBE1
and ADAMTS3 in adult lymphangiogenesis. Further investigations on the VEGFCADAMTS3-CCBE1 complex are required to gain deeper knowledge and practical
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understanding to identify a potential cure for impaired lymphatic vasculature; it is a
glimpse of hope for patients with lymphedema.
In conclusion, our research has contributed to the discovery of such diverse and complex
regulatory mechanisms in which VEGFC activation reveals an unexpected complexity in
the control of lymphatic vascular growth. While further studies are necessary to translate
our findings into therapeutic applications for lymphatic defects in human, understanding
of VEGFC/ CCBE1/ ADAMTS3 pathway should encourage use of these growth factors
in therapy for lymphatic diseases including lymphedema.
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